Metrikler
Yayın
364
Açık Erişim
24
BM Sürdürülebilir Kalkınma Amaçları
Biyografi
1978 yılında Rize’de doğan Yusuf Yılmaz 1996 yılında İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi’ni kazanarak dereceyle mezun olma başarısını göstererek 2002 yılında ‘Tıp Doktoru’ ünvanını almıştır. Aynı yıl tıpta uzmanlık sınavını kazanarak Uludağ Üniversitesi Tıp Fakültesi’ne girmiş, 2007 yılında ‘İç Hastalıkları Uzmanı’ olmuştur. Kısa bir süre zorunlu hizmet görevini yerine getirerek 2008 yılında kazandığı yan dal sınavı ile Marmara Üniversitesi Tıp Fakültesi Gastroenteroloji Bilim Dalı’nda yan dal uzmanlık eğitimine başlamıştır. 2011 yılında ‘Gastroenteroloji Uzmanı’ da olan ve aynı yıl Doçentlik sınavını da başarıyla veren Yusuf Yılmaz 2012 yılında Marmara Üniversitesi Tıp Fakültesi’ne ‘Öğretim Üyesi’ olarak atanmıştır. 2017 yılında tıp fakültesine atanan en genç ‘Profesör’ olmuştur. 2018 yılında dünyada 'Tıp Bilimine Yön Veren 100 Türk' arasına girmiştir.
Prof. Dr. Yusuf Yılmaz’ın uluslararası yabancı dergilerde yayımlanmış 150’ye yakın bilimsel araştırması bulunmaktadır. Uluslarası bir kuruluş olan Webometrics 2016 verilerine göre Dr. Yusuf Yılmaz, Türkiye’deki tüm bilim insanları içerisinde (sadece tıp alanında değil) 223. sıraya yerleşme başarısına bu genç yaşında ulaşmıştır. Google Akademik 2018 verilerine göre >30 h endeksi ve 4000 alıntılanma sayısı ile ülkemizin en iyi akademisyenleri arasında gösterilmektedir.
Yüksek özverili çalışmaları sayesinde alanında sadece dünyaca ünlü bilim insanlarının davet edilerek derlemelerinin yayımlandığı prestijli dergilerde yazar olma başarısını göstermiştir. Bütün bu başarılar sayesinde uluslararası NASH komitesine seçilen Avrupa’dan sayılı birkaç bilim insanından biridir. Ayrıca Avrupa Karaciğer Araştırmaları Derneği, Amerikan Karaciğer Araştırmaları Derneği, Amerikan Kronik Karaciğer Vakfı üyeliği bulunmaktadır.
Hepatology, Journal of Hepatology, Alimantary Pharmacology and Therapeutics, Diabetes Care , Metabolism gibi 50’den fazla uluslararası dergide hakemlik görevi bulunmaktadır. Çeşitli yıllarda en iyi hakem, en fazla alıntı yapılan araştırma, en çok alıntı yapılan derleme sahibi bilim insanı başarısını da göstermiştir.
Türkiye’de Fibroscan kullanımında en deneyimli kişi olan Prof. Dr. Yusuf Yılmaz, bu deneyimini gerek yurt içinde gerekse yurt dışında hekimlere yönelik eğitim kurslarıyla meslektaşlarıyla paylaşmaktadır.
Eğitim Bilgileri
2008 - 2011
2008 - 2011Tıpta Yandal Uzmanlık
Marmara Üniversitesi, Tıp Fakültesi, Türkiye
2002 - 2007
2002 - 2007Tıpta Uzmanlık
Uludağ Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Türkiye
1996 - 2002
1996 - 2002Lisans
İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Türkiye
Yabancı Diller
C1 İleri
C1 İleriİngilizce
Araştırma Alanları
Tıp
Sağlık Bilimleri
Dahili Tıp Bilimleri
İç Hastalıkları
Gastroenteroloji-(Hepatoloji)
Akademik Ünvanlar / Görevler
2017 - Devam Ediyor
2017 - Devam EdiyorProf. Dr.
Marmara Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
Yönetimsel Görevler
2014 - Devam Ediyor
2014 - Devam EdiyorEnstitü Müdürü
Marmara Üniversitesi, Gastroenteroloji Enstitüsü
Akademi Dışı Deneyim
2008 - 2008
2008 - 2008Zorunlu Hizmet
Şanlıurfa Siverek Devlet Hastanesi, Zorunlu Hizmet
Yönetilen Tezler
2020
2020Tıpta Uzmanlık
OBEZ HASTALARDA KARACİĞER YAĞLANMASININ VE FİBROZİSİNİN FİBROSCAN İLENONİNVAZİV OLARAK DEĞERLENDİRİLMESİ
Yılmaz Y. (Danışman)
A.AVCU(Öğrenci)
2019
2019Tıpta Uzmanlık
Fibroscan'in nonalkolik yağlı karaciğer hastalığındaki tanısal performansının değerlendirilmesi
Yılmaz Y. (Danışman)
F.JAFAROV(Öğrenci)
2019
2019Tıpta Uzmanlık
Biyopsi kanıtlı non-alkolik yağlı karaciğer hastalığı bulunan bireylerde tip 2 diabetes mellitus, metabolik sendrom ve obezite prevalansının değerlendirilmesi
Yılmaz Y. (Danışman)
H.JAFAROVA(Öğrenci)
2019
2019Yüksek Lisans
Alkolik olmayan karaciğer yağlanması olan hastalarda bağırsaktaki faecalibacterium prausnitzii ve eubacterium rectale bakterilerinin değişimlerinin uygulanan diyet modeli ile ilişkilendirilmesi
Güneş F. E., Yılmaz Y. (Eş Danışman)
E.OĞUZ(Öğrenci)
2019
2019Tıpta Uzmanlık
Nonalkolik karaciğer yağlanması bulunan hastalarda aterosklerozun ve karaciğer sertliğinin noninvazifdeğerlendirilmesi
Yılmaz Y. (Danışman)
B.Ören(Öğrenci)
2019
2019Tıpta Uzmanlık
Fibroscan’in nonalkolik yağlı karaciğer hastalığındaki tanısal performansının değerlendirilmesi
Yılmaz Y. (Danışman)
F.Jafarov(Öğrenci)
2018
2018Doktora
Normal kilolu non-alkolik yağlı karaciğer hastalığı olan bireylerde tıbbi beslenme tedavisinin etkinliğinin değerlendirilmesi
Tüfekçi Alphan M. E., Yılmaz Y. (Eş Danışman)
P.HAMURCU(Öğrenci)
2018
2018Tıpta Uzmanlık
Tip 2 diyabetli hastalarda karaciğer sertliğinin ve yağlanmasının Fibroscan ile saptanması
Yılmaz Y. (Danışman)
M.Demir(Öğrenci)
2015
2015Tıpta Uzmanlık
Non-alkolik yağlı karaciğerli hastalarda ileri evre fibrozisin saptanmasında non-invaziv fibrozis testlerinin tanısal performansı
Yılmaz Y. (Danışman)
C.FIRAT(Öğrenci)
2015
2015Tıpta Uzmanlık
Nonalkolik yağlı karaciğerli hastalarda ileri evre fibrozisin saptanmasında noninvaziv yeni bir yöntem olan fibrometer VCTE'nin tanısal performansı
Yılmaz Y. (Danışman)
E.DİNÇSES(Öğrenci)
2015
2015Tıpta Uzmanlık
Nonalkolik yağlı karaciğerli hastalarda ileri evre fibrozisin saptanmasında noninvaziv yeni bir yöntem olan fibrometertm vcte'nin tanısal performansı
YILMAZ Y. (Danışman)
E.Dinçses(Öğrenci)
2014
2014Tıpta Uzmanlık
Nonalkolik yağlı karaciğer hastalığında fibrozisin noninvaziv yöntemlerle araştırılması
Yılmaz Y. (Danışman)
U.EMRE(Öğrenci)
Makaleler
Tümü (241)
SCI-E, SSCI, AHCI (226)
SCI-E, SSCI, AHCI, ESCI (236)
ESCI (8)
Scopus (232)
TRDizin (19)
Diğer Yayınlar (6)
2025
20251. Effects of Intermittent Fasting on Liver Steatosis and Fibrosis, Serum FGF-21 and Autophagy Markers in Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized Controlled Trial
Karahan T. O., Akyuz E. Y., Karadag D. Y., Yilmaz Y., Eren F.
LIFE-BASEL
, cilt.15, sa.5, ss.1-19, 2025 (SCI-Expanded, Scopus)
2025
20252. Clinical and Biochemical Characteristics of a Danish and Turkish Cohort of Incident and Prevalent Patients with Primary Biliary Cholangitis
Eruzun H., Bossen L., Gökçe D. T., Ergenç İ., Harput Z. N., Aydemir N. G., et al.
Turkish Journal of Gastroenterology
, cilt.36, sa.4, ss.241-246, 2025 (SCI-Expanded)
2023
20233. Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
Anstee Q. M., Lucas K. J., Francque S., Abdelmalek M. F., Sanyal A. J., Ratziu V., et al.
Hepatology
, cilt.78, sa.4, ss.1223-1239, 2023 (SCI-Expanded)
2023
20234. An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Zhou X., Targher G., Byrne C. D., Somers V., Kim S. U., Chahal C. A. A., et al.
Hepatology International
, cilt.17, sa.4, ss.773-791, 2023 (SCI-Expanded)
2023
20235. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease
Sun D., Targher G., Byrne C. D., Wheeler D. C., Wong V. W., Fan J., et al.
HEPATOBILIARY SURGERY AND NUTRITION
, cilt.12, sa.3, 2023 (SCI-Expanded)
2023
20236. TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease.
Yılmaz Y., Zeybel M., Adalı G., Coşar A., Sertesen E., Sümer H., et al.
Hepatology forum
, cilt.4, sa.Suppl 1, ss.1-32, 2023 (ESCI)
2023
20237. Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice
Lazarus J. V., Castera L., Mark H. E., Allen A. M., Adams L. A., Anstee Q. M., et al.
JHEP Reports
, cilt.5, sa.1, 2023 (SCI-Expanded)
2023
20238. Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan
Yesil E. E., YILMAZ Y., Yesil A., Mese M., Kaya E., Bakir E. A.
HEPATOLOGY FORUM
, cilt.4, sa.1, ss.14-18, 2023 (ESCI)
2023
20239. Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study
YILMAZ Y., Toraman A. E., Alp C., Dogan Z., Keklikkiran C., Stepanova M., et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
, cilt.57, sa.2, ss.215-223, 2023 (SCI-Expanded)
2022
202210. The effects of dietary intervention on fibrosis and biochemical parameters in metabolic-associated fatty liver disease.
Ozlu T., Yilmaz Y., Gunes F. E.
Minerva gastroenterology
, cilt.68, ss.426-433, 2022 (SCI-Expanded)
2022
202211. Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registry
Younossi Z. M., Yu M., El-Kassas M., Esmat G., Fernandez M. I. C., Buti M., et al.
JOURNAL OF VIRAL HEPATITIS
, cilt.29, sa.11, ss.1015-1025, 2022 (SCI-Expanded)
2022
202212. CLINICAL AND PATIENT-REPORTED OUTCOME (PRO) PROFILE OF PATIENTS WITH HEPATITIS B VIRAL (HBV) INFECTION FROM THE GLOBAL LIVER REGISTRY (TM) (GLR (TM))
Younossi Z. M., YILMAZ Y., Yu M., Alswat K. A., Buti M., Fernandez M. I. C., et al.
HEPATOLOGY
, cilt.76, 2022 (SCI-Expanded)
2022
202213. DEPRESSION AND EMOTIONAL DISTRESS IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY (TM) (GLR (TM))
Younossi Z. M., Stepanova M., Fernandez M. I. C., YILMAZ Y., Yu M., El Kassas M., et al.
HEPATOLOGY
, cilt.76, 2022 (SCI-Expanded)
2022
202214. REAL-WORLD EVIDENCE ON NON-INVASIVE TESTS AND ASSOCIATED CUT-OFFS USED TO ASSESS FIBROSIS IN ROUTINE CLINICAL PRACTICE
Lazarus J. V., Castera L., Mark H., Adams L. A., Allen A. M., Anstee Q. M., et al.
HEPATOLOGY
, cilt.76, 2022 (SCI-Expanded)
2022
202215. The impact of the COVID-19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry
Younossi Z. M., Yilmaz Y., El-Kassas M., Duseja A., Hamid S., Esmat G., et al.
HEPATOLOGY COMMUNICATIONS
, cilt.6, sa.10, ss.2860-2866, 2022 (SCI-Expanded)
2022
202216. Clinical and Patient Reported Outcomes from Patients with Non-alcoholic Fatty Liver Disease Across the World: Data from the Global NASH/NAFLD Registry.
Younossi Z. M., Yilmaz Y., Yu M., Wai-Sun Wong V., Fernandez M. C., Isakov V. A., et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
, cilt.20, sa.10, ss.2296, 2022 (SCI-Expanded)
2022
202217. Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease
Younossi Z., Yilmaz Y., El Kassas M., Duseja A. K., Hamid S. S., Esmat G., et al.
JOURNAL OF HEPATOLOGY
, cilt.77, 2022 (SCI-Expanded)
2022
202218. Multimodality assessment of hepatic fibrosis: ranked paired reading and artificial intelligence identifies fibrosis improvement with aramchol missed by conventional staging
Ratziu V., Yilmaz Y., Lazas D., Friedman S., Lackner C., Behling C., et al.
JOURNAL OF HEPATOLOGY
, cilt.77, 2022 (SCI-Expanded)
2022
202219. Lean non-alcoholic fatty liver disease patients from the global NASH registry
Younossi Z., Yilmaz Y., Yu M., Wong V. W., Castellanos-Fernandez M., Isakov V., et al.
JOURNAL OF HEPATOLOGY
, cilt.77, 2022 (SCI-Expanded)
2022
202220. Higher daily Aramchol dose results in higher effect size in fibrosis improvement in the ARMOR study open label part
Ratziu V., Yilmaz Y., Lazas D., Friedman S., Hayardeny L., Kadosh S., et al.
JOURNAL OF HEPATOLOGY
, cilt.77, 2022 (SCI-Expanded)
2022
202221. A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease.
Younossi Z. M., Ong J. P., Takahashi H., Yilmaz Y., Eguchi Y., El Kassas M., et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
, cilt.20, 2022 (SCI-Expanded)
2022
202222. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
Mózes F. E., Lee J. A., Selvaraj E. A., Jayaswal A. N. A., Trauner M., Boursier J., et al.
Gut
, cilt.71, ss.1006-1019, 2022 (SCI-Expanded)
2022
202223. Global multi-stakeholder endorsement of the MAFLD definition.
Méndez-Sánchez N., Bugianesi E., Gish R. G., Lammert F., Tilg H., Nguyen M. H., et al.
The lancet. Gastroenterology & hepatology
, cilt.7, sa.5, ss.388-390, 2022 (SCI-Expanded)
2022
202224. Insidious danger for young adults: Metabolic (dysfunction)associated fatty liver disease
Kaya E., YILMAZ Y.
HEPATOLOGY FORUM
, cilt.3, sa.2, ss.39-40, 2022 (ESCI)
2022
202225. Fibroscan detection of fatty liver and liver fibrosis in patients with systemic lupus erythematosus.
Yetginoglu O., Atas D., Yilmaz Y., Velioglu A., Arikan H., Alibaz-Oner F., et al.
Lupus
, cilt.31, sa.6, ss.723-729, 2022 (SCI-Expanded)
2022
202226. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
Lazarus J. V., Mark H. E., Villota-Rivas M., Palayew A., Carrieri P., Colombo M., et al.
Journal of hepatology
, cilt.76, ss.771-780, 2022 (SCI-Expanded)
2022
202227. Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver
Kaya E., Yılmaz Y.
Journal of Clinical and Translational Hepatology
, cilt.10, sa.2, ss.329-338, 2022 (SCI-Expanded)
2022
202228. Advancing the global public health agenda for NAFLD: a consensus statement
Lazarus J., Mark H. E., Anstee Q. M., Arab J. P., Batterham R. L., Castera L., et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
, cilt.19, ss.60-78, 2022 (SCI-Expanded)
2022
202229. Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals.
Eren F., Kaya E., Yilmaz Y.
European journal of gastroenterology & hepatology
, cilt.34, ss.98-103, 2022 (SCI-Expanded, Scopus)
2022
202230. Prevention of hepatocellular carcinoma and surveillance of high risk patients
Kaya E., Mazzolini G. D., YILMAZ Y., CANBAY A.
Hepatology Forum
, cilt.3, ss.33-38, 2022 (ESCI)
2021
202131. Macro- and micronutrients in metabolic (dysfunction) associated fatty liver disease: association between advanced fibrosis and high dietary intake of cholesterol/saturated fatty acids.
Guveli H., Kenger E. B., Ozlu T., Kaya E., Yilmaz Y.
European journal of gastroenterology & hepatology
, cilt.33, 2021 (SCI-Expanded)
2021
202132. Demographic Characteristics and Transmission Risk Factors of Patients with Hepatitis C Virus in Turkey: The EPI-C, A Multicenter and Cross-sectional Trial
TABAK F., ŞİRİN G., DEMİR M., ALADAĞ M., SÜMER Ş., KURTARAN B., et al.
Viral Hepatitis Journal
, cilt.27, sa.3, ss.109-117, 2021 (ESCI)
2021
202133. A NOVEL STUDY DESIGN WITH ARAMCHOL EXPLORING THE KINETICS AND INTER-RELATIONS OF HISTOLOGICAL OUTCOME MEASURES AND NON-INVASIVE TESTS ASSOCIATED WITH NASH AND FIBROSIS FOR VARIABLE TREATMENT DURATIONS
Ratziu V., YILMAZ Y., Lazas D., De Guevara L. L., Kadosh S., Gorfine T., et al.
HEPATOLOGY
, cilt.74, 2021 (SCI-Expanded)
2021
202134. COVID-19 PANDEMIC AND CHRONIC LIVER DISEASE (CLD)
Younossi Z. M., YILMAZ Y., El Kassas M., Duseja A. K., Hamid S. S., Esmat G., et al.
HEPATOLOGY
, cilt.74, 2021 (SCI-Expanded)
2021
202135. FATIGUE AND NON-ALCOHOLIC FATTY LIVER DISEASE: DATA FROM THE GLOBAL NASH REGISTRY
Younossi Z. M., YILMAZ Y., Wong V. W., Fernandez M. I. C., Bugianesi E., Burra P., et al.
HEPATOLOGY
, cilt.74, 2021 (SCI-Expanded)
2021
202136. acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study.
Wu X., Zheng K. I., Boursier J., Chan W., Yilmaz Y., Romero-Gómez M., et al.
EClinicalMedicine
, cilt.41, ss.101145, 2021 (SCI-Expanded)
2021
202137. Liver stiffness is associated with disease severity and worse clinical scenarios in coronavirus disease 2019: A prospective transient elastography study
Demirtas C. O., Keklikkiran C., Ergenc I., Erturk Sengel B., Eskidemir G., Cinel I., et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
, cilt.75, sa.9, 2021 (SCI-Expanded)
2021
202138. Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
KANİ H. T., DEMİRTAŞ C. Ö., KEKLİKKIRAN Ç., Ergenc I., Mehdiyev S., AKDENİZ E., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY
, cilt.32, sa.8, ss.661-666, 2021 (SCI-Expanded)
2021
202139. Individual patient data meta-analysis of the diagnostic performance of single and sequentially combined non-invasive tests in detecting advanced fibrosis
Mozes F., Lee J., Selvaraj E., Jayaswal A., Trauner M., Boursier J., et al.
JOURNAL OF HEPATOLOGY
, cilt.75, 2021 (SCI-Expanded)
2021
202140. The Impact of COVID-19 Pandemic on Patients with Chronic Liver Disease (CLD): Data from the Global Registry
Younossi Z., YILMAZ Y., El-Kassas M., Duseja A. K., Hamid S. S., Esmat G., et al.
JOURNAL OF HEPATOLOGY
, cilt.75, 2021 (SCI-Expanded)
2021
202141. Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement.
Hagström H., Adams L. A., Allen A. M., Byrne C. D., Chang Y., Grønbaek H., et al.
Hepatology (Baltimore, Md.)
, cilt.74, ss.474-482, 2021 (SCI-Expanded)
2021
202142. Development and validation of Agile 3+: novel FibroScan based score for the diagnosis of advanced fibrosis in patients with nonalcoholic fatty liver disease
Younossi Z., Harrison S., Newsome P. N., Chan W., YILMAZ Y., de Ledinghen V., et al.
JOURNAL OF HEPATOLOGY
, cilt.75, 2021 (SCI-Expanded)
2021
202143. Editorial: liver stiffness by magnetic resonance elastography and cardiovascular risk in non-alcoholic fatty liver disease-simply associated or more complicated?
Demirtas C. O., Yilmaz Y.
Alimentary pharmacology & therapeutics
, cilt.53, ss.1228-1229, 2021 (SCI-Expanded)
2021
202144. Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic
AVCU A., Kaya E., YILMAZ Y.
TURKISH JOURNAL OF GASTROENTEROLOGY
, cilt.32, sa.5, ss.466-472, 2021 (SCI-Expanded)
2021
202145. FIBROSCAN DETECTION OF FATTY LIVER AND LIVER FIBROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS
YETGİNOĞLU Ö., Atas D. B., VELİOĞLU A., ARIKAN İ. H., YILMAZ Y., ALİBAZ ÖNER F., et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION
, cilt.36, ss.172, 2021 (SCI-Expanded)
2021
202146. The prevalence of metabolic-associated fatty liver disease in the Turkish population: A multicenter study
YILMAZ Y., YILMAZ N., ATEŞ F., KARAKAYA F., GÖKCAN H., KAYA E., et al.
Hepatology Forum
, cilt.2, sa.2, ss.37-42, 2021 (ESCI)
2021
202147. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD.
Yilmaz Y., Byrne C., Musso G.
Expert review of gastroenterology & hepatology
, cilt.15, ss.345-352, 2021 (SCI-Expanded)
2021
202148. Recommendations for Reopening Endoscopy Units in Turkey: A Set-up Plan from a Tertiary Center in Istanbul.
Demirtas C. Ö., Keklikkıran Ç., Mehdiyev S., Ergenç İ., Özen Alahdab Y., Gündüz F., et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
, cilt.32, ss.113-115, 2021 (SCI-Expanded)
2021
202149. High incidence of hepatitis B core antibody positivity in metabolic-associated fatty liver disease-related cirrhosis.
ERGENÇ İ., GÖKÇEN P., ADALI G., Kani H. T., Demirtaş C. Ö., Gündüz F., et al.
Hepatology forum
, cilt.2, sa.1, ss.20-25, 2021 (Scopus)
2021
202150. Comparison of aerobic and combined aerobic and whole-body vibration training effects on physical fitness in non-alcoholic fatty liver patients
Saldiran T. C., Mutluay F. K., Yagci İ., Yilmaz Y.
COMPARATIVE EXERCISE PHYSIOLOGY
, cilt.17, sa.4, ss.393-401, 2021 (ESCI)
2021
202151. The case for simplifying and using absolute targets for viral hepatitis elimination goals.
Razavi H., Blach S., Razavi-Shearer D., Polaris O.
Journal of viral hepatitis
, cilt.28, ss.12-19, 2021 (SCI-Expanded)
2020
202052. Letter: the use of Fibrosis-4 score in primary care and diabetology practices-Occam's razor applied to advanced fibrosis screening.
Yilmaz Y., Kaya E., Eren F.
Alimentary pharmacology & therapeutics
, cilt.52, ss.1759-1760, 2020 (SCI-Expanded, Scopus)
2020
202053. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Eslam M., Sarin S., Wong V., Fan J., Kawaguchi T., Ahn S., et al.
HEPATOLOGY INTERNATIONAL
, cilt.14, sa.6, ss.889-919, 2020 (SCI-Expanded)
2020
202054. Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients.
Hamurcu V., Kaya E., Alphan E., Yilmaz Y.
European journal of gastroenterology & hepatology
, cilt.32, ss.1352-1357, 2020 (SCI-Expanded)
2020
202055. Effect of carbon dioxide versus room air insufflation on post-colonoscopic pain: A prospective, randomized, controlled study.
Gündüz F., Kani H. T., Chang S., Akdeniz E., Eren F., Yılmaz Y., et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
, cilt.31, sa.10, ss.676-680, 2020 (SCI-Expanded, Scopus, TRDizin)
2020
202056. Impact of aerobic training with and without whole-body vibration training on metabolic features and quality of life in non-alcoholic fatty liver disease patients.
Saldıran T., Mutluay F., Yağcı İ., Yılmaz Y.
Annales d'endocrinologie
, cilt.81, ss.493-499, 2020 (SCI-Expanded)
2020
202057. Metabolic-associated Fatty Liver Disease: Time to integrate ground-breaking new terminology to our clinical practice?
DEMİRTAŞ C. Ö., YILMAZ Y.
Hepatology Forum
, cilt.1, sa.3, ss.79-81, 2020 (Hakemli Dergi)
2020
202058. Regular coffee intake improves liver enzyme levels and liver histology in patients with chronic alcohol consumption, non-alcoholic fatty liver and non-alcoholic steatohepatitis: Report of 259 cases
DEĞERTEKİN M. B., TÖZÜN A. N., Söylemez A. G., Gurtay E., Bozkurt U., YILMAZ Y., et al.
Hepatology Forum
, cilt.1, sa.3, ss.88-96, 2020 (Hakemli Dergi)
2020
202059. Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD.
Sun D., Ye F., Kani H. T., Yang J., Zheng K., Zhang H., et al.
Diabetes & metabolism
, cilt.46, sa.4, ss.288-295, 2020 (SCI-Expanded)
2020
202060. The clinical and histological characteristics of patients with biopsy-proven non-alcoholic fatty liver disease in the absence of insulin resistance
DEMİRTAŞ C. Ö., SAPMAZ A., GÜREL B. A., KIZMAZ H., ULU T., KARAKETİR Ş. G., et al.
Hepatology Forum
, cilt.1, sa.3, ss.101-108, 2020 (Hakemli Dergi)
2020
202061. Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease.
Kaya E., Bakir A., Kani H. T., Demirtas C., Keklikkiran C., Yilmaz Y.
Gut and liver
, cilt.14, sa.4, ss.486-491, 2020 (SCI-Expanded)
2020
202062. External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients.
Demirtas C., Gunduz F., Kani H. T., Keklikkıran C., Alahdab Y., Yılmaz Y., et al.
European journal of gastroenterology & hepatology
, cilt.32, sa.7, ss.882-888, 2020 (SCI-Expanded)
2020
202063. A new definition for metabolic associated fatty liver disease: an international expert consensus statement.
Eslam M., Newsome P., Anstee Q., Targher G., Gomez M., Zelber-Sagi S., et al.
Journal of hepatology
, cilt.73, ss.202-209, 2020 (SCI-Expanded)
2020
202064. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease.
Alkayyali T., Qutranji L., Kaya E., Bakir A., Yilmaz Y.
Acta diabetologica
, cilt.57, sa.5, ss.613-618, 2020 (SCI-Expanded)
2020
202065. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.
Eslam M., Sanyal A., George J., International C.
Gastroenterology
, cilt.158, 2020 (SCI-Expanded)
2020
202066. The interaction between current smoking and hemoglobin on the risk of advanced fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease.
Enc F., Ulasoglu C., Bakir A., Yilmaz Y.
European journal of gastroenterology & hepatology
, cilt.32, ss.597-600, 2020 (SCI-Expanded)
2020
202067. The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study
Jafarov F., Kaya E., Bakir A., Eren F., Yilmaz Y.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
, cilt.32, ss.642-649, 2020 (SCI-Expanded, Scopus)
2020
202068. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome P., Sasso M., Deeks J., Paredes A., Boursier J., Chan W., et al.
The lancet. Gastroenterology & hepatology
, cilt.5, ss.362-373, 2020 (SCI-Expanded)
2020
202069. Letter: the perilous road to a functional cure for hepatitis B infection.
Yilmaz Y.
Alimentary pharmacology & therapeutics
, cilt.51, ss.577, 2020 (SCI-Expanded)
2020
202070. Letter: a stepwise approach towards the screening of hepatic fibrosis in the general population.
Yilmaz Y.
Alimentary pharmacology & therapeutics
, cilt.51, ss.669-670, 2020 (SCI-Expanded)
2020
202071. The comparison of resting metabolic rate betweenbiopsy-proven non-alcoholic steatohepatitis andnon-alcoholic fatty liver patients
KENGER E. B., GÜVELİ H., Ergun C., Kaya E., YILMAZ Y.
Hepatology Forum
, cilt.1, sa.1, ss.14-19, 2020 (Hakemli Dergi)
2020
202072. The utility of noninvasive scores in non-alcoholic fatty liver disease patients with normal and elevated serum transaminases
Kaya E., Bakır A., Eren F., Yılmaz Y.
Hepatology Forum
, cilt.1, sa.1, ss.8-13, 2020 (Hakemli Dergi)
2020
202073. Arterial stiffness is associated independently with liver stiffness in biopsy-proven nonalcoholic fatty liver disease: a transient elastography study.
Bilgin B., Sunbul M., Kani H. T., Demirtas C., Keklikkiran C., Yilmaz Y.
European journal of gastroenterology & hepatology
, cilt.32, ss.54-57, 2020 (SCI-Expanded)
2020
202074. NFS Is Not a Marker of Nonalcoholic Fatty Liver Disease Per Se: What Is the True Relationship With CAD Complexity?
Yılmaz Y., Eren F.
ANGIOLOGY
, cilt.71, ss.83-84, 2020 (SCI-Expanded)
2019
201975. Characterization of Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease and Normal Aminotransferase Levels.
Ulasoglu C., Enc F., Kaya E., Yilmaz Y.
Journal of gastrointestinal and liver diseases : JGLD
, cilt.28, ss.427-431, 2019 (SCI-Expanded)
2019
201976. Transient elastography for assessing severe hepatic fibrosis in diabetic patients with nonalcoholic fatty liver disease: definitions matter
Yilmaz Y., Eren F.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
, cilt.31, sa.12, ss.1601-1602, 2019 (SCI-Expanded)
2019
201977. Comments on "The Effect of Laparoscopic Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease"
Yılmaz Y., Eren F.
SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES
, cilt.29, sa.6, ss.548, 2019 (SCI-Expanded)
2019
201978. Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.
Tatar B., Köse Ş., Ergun N., Turken M., Onlen Y., Yılmaz Y., et al.
Revista da Associacao Medica Brasileira (1992)
, cilt.65, ss.1470-1475, 2019 (SCI-Expanded)
2019
201979. Potential clinical variants detected in mitochondrial DNA D-loop hypervariable region I of patients with non-alcoholic steatohepatitis
Hasturk B., Yilmaz Y., Eren F.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM
, cilt.18, ss.463-475, 2019 (SCI-Expanded, Scopus)
2019
201980. Hepatic fibrosis - and not steatosis - is the main determinant of arterial stiffness in non-alcoholic fatty liver disease
Yilmaz Y., Eren F.
ATHEROSCLEROSIS
, cilt.290, ss.222-223, 2019 (SCI-Expanded, Scopus)
2019
201981. Non-alcoholic fatty liver disease: A growing public health problem in Turkey
Kaya E., YILMAZ Y.
TURKISH JOURNAL OF GASTROENTEROLOGY
, cilt.30, sa.10, ss.865-871, 2019 (SCI-Expanded)
2019
201982. Evaluation of depression, anxiety and quality of life in hepatitis C patients who treated with direct acting antiviral agents
Kesen O., Kani H. T., Yanartaş Ö., Aykut U., Gök B., Gündüz F., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY
, cilt.30, sa.9, ss.801-806, 2019 (SCI-Expanded)
2019
201983. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease
Younossi Z. M., Stepanova M., Ong J., Yılmaz Y., Duseja A., Eguchi Y., et al.
Clinical Gastroenterology and Hepatology
, cilt.17, ss.1625, 2019 (SCI-Expanded)
2019
201984. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Younossi Z., Tacke F., Arrese M., Chander Sharma B., Mostafa I., Bugianesi E., et al.
Hepatology
, cilt.69, ss.2672-2682, 2019 (SCI-Expanded)
2019
201985. Liver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease
Dq S., Fang Zhoe Y., KANİ H. T., Chen Fei Z., Pei Wu Z., Hong Lei M., et al.
Journal Of Hepatology
, cilt.70, ss.787, 2019 (SCI-Expanded)
2019
201986. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study
DEMİR M., Deyneli O., YILMAZ Y.
TURKISH JOURNAL OF GASTROENTEROLOGY
, cilt.30, sa.3, ss.266-270, 2019 (SCI-Expanded)
2019
201987. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
Younossi Z., Stepanova M., Ong J. P., Jacobson I. M., Bugianesi E., Duseja A., et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
, cilt.17, sa.4, ss.748-758, 2019 (SCI-Expanded)
2019
201988. The optimal controlled attenuation parameter cut-offs in hepaticsteatosis grade differentiation by transient elastography(Fibroscan) in a sample of biopsy-proven non-alcoholic fatty liverdisease patients
Kaya E., BAKIR A., Sapmaz A. F., Kayyali T., Quatranji L., Çiftaslan A., et al.
Hepatology International
, cilt.13, ss.196, 2019 (SCI-Expanded)
2019
201989. Prevalence of fatty liver disease in patients with inflammatory bowel disease: a transient elastography study on the basis of a controlled attenuation parameter
Kani H. T., Deliktas I., YILMAZ Y.
MARMARA MEDICAL JOURNAL
, cilt.32, sa.2, ss.68-70, 2019 (ESCI)
2019
201990. Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology
YILMAZ Y., EREN F.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
, cilt.31, sa.1, ss.43-46, 2019 (SCI-Expanded, Scopus)
2019
201991. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
Yılmaz Y., Kani H. T., Demirtaş C., Kaya E., Sapmaz A., Qutranji L., et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
, cilt.30, ss.892-898, 2019 (SCI-Expanded)
2018
201892. Nonalcoholic Fatty Liver Disease(NAFLD) and Alcoholic Fatty Lİver Disease(AFLD): The impact of Alcohol Comsumpt,on and Metabolic Syndrome on Mortality
Younossi Z., Maria S., Ong J., Yılmaz Y., Duseja A., Eguchi Y., et al.
Hepatology , cilt.68, ss.1, 2018 (SCI-Expanded)
2018
201893. THE SEQUENCE ANALYSIS OF NEW MITOCHONDRIALGENE, MOTS-C, IN PATIENTS WITH THE NON-ALCOHOLICSTEATOHEPATITIS
Önal O., Eren F., Yılmaz D., Göçmen T., Yılmaz Y.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL , cilt.6, ss.135, 2018 (SCI-Expanded)
2018
201894. Development of multiplex single base primer extension assay for the detection of potential association between MTNR1B gene polymorphisms and NASH
Yılmaz D., Eren F., Göçmen T., Yılmaz Y.
Journal Of Biotechnology
, cilt.280, ss.76, 2018 (SCI-Expanded, Scopus)
2018
201895. The association of fatty pancreas with subclinical atherosclerosis in nonalcoholic fatty liver disease
Ozturk K., Dogan T., Celikkanat S., Ozen A., Demirci H., Kurt O., et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
, cilt.30, sa.4, ss.411-417, 2018 (SCI-Expanded)
2018
201896. The correlation between histopathologic steatosis/fibrosis and various non-invasive imagingand blood fibrosis indicators of overweight and obese children
Tutar E., Şahin Akkelle B., Kesici C. B., Yılmaz Y., Çelikel Ç., Ergelen R., et al.
Journal Of Pediatric Gastroenterology And Nutrition , cilt.66, 2018 (SCI-Expanded)
2018
201897. Transient elastography with controlled attenuation parameter in the assessment of hepatic steatosis and significant liver fibrosis in patients with scleroderma
Yılmaz Y., Kani H. T., Şahinkaya Y., Deliktaş İ., Mursaloğlu H. H., Aziziy M., et al.
Hepatology International , cilt.12, 2018 (SCI-Expanded)
2017
201798. Recommendation for treatment of hepatitis C virus infection
KAYMAKOĞLU S., Koksal I., KAYMAKOĞLU S., Tabak F., Akarca U. S., Akbulut A., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY
, cilt.28, 2017 (SCI-Expanded)
2017
201799. Nonalcoholic steatohepatitis and gut microbiota: Future perspectives on probiotics in metabolic liver diseases
YILMAZ Y., EREN F.
TURKISH JOURNAL OF GASTROENTEROLOGY
, cilt.28, sa.5, ss.327-328, 2017 (SCI-Expanded, Scopus, TRDizin)
2017
2017100. The association of nonalcoholic fatty liver disease with genetic polymorphisms: A multicenter study
Uygun A., Ozturk K., Demirci H., Oztuna A., Eren F., Kozan S., et al.
European Journal of Gastroenterology and Hepatology
, cilt.29, ss.441-447, 2017 (SCI-Expanded, Scopus)
2016
2016101. Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter
Kaya E., Demir D., ÖZEN ALAHDAB Y., YILMAZ Y.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
, cilt.28, sa.11, ss.1264-1267, 2016 (SCI-Expanded)
2016
2016102. Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis
ERGELEN R., YILMAZ Y., Asedov R., ÇELİKEL Ç., Akin H., BUĞDAYCI O., et al.
ABDOMINAL RADIOLOGY
, cilt.41, sa.8, ss.1505-1510, 2016 (SCI-Expanded)
2016
2016103. The role of active brown adipose tissue in human metabolism
Ozguven S., Ones T., Yilmaz Y., Turoglu H. T., Imeryuz N.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
, cilt.43, sa.2, ss.355-361, 2016 (SCI-Expanded)
2016
2016104. Diagnostic Role of Colon Capsule Endoscopy in Patients with Optimal Colon Cleaning
Akyüz Ü., Yılmaz Y., Ince A. T., Kaya B., Pata C.
Gastroenterology Research and Practice
, cilt.2016, 2016 (SCI-Expanded)
2016
2016105. Is NAFLD different in absence of metabolic syndrome?
YILMAZ Y.
CLINICAL DILEMMAS IN NON-ALCOHOLIC FATTY LIVER DISEASE
, ss.44-49, 2016 (SCI-Expanded)
2015
2015106. Nonalcoholic Steatohepatitis Score is an Independent Predictor of Right Ventricular Dysfunction in Patients with Nonalcoholic Fatty Liver Disease
Sünbül M., Kivrak T., Durmus E., Akin H., Aydin Y., Ergelen R., et al.
CARDIOVASCULAR THERAPEUTICS
, cilt.33, ss.294-299, 2015 (SCI-Expanded)
2015
2015107. Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease
Dincses E., YILMAZ Y.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
, cilt.27, sa.10, ss.1149-1153, 2015 (SCI-Expanded)
2015
2015108. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease
Ozturk O., ÇOLAK Y., ŞENATEŞ E., YILMAZ Y., Ulasoglu C., Doganay L., et al.
WORLD JOURNAL OF GASTROENTEROLOGY
, cilt.21, sa.26, ss.8096-8102, 2015 (SCI-Expanded)
2015
2015109. Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease
ERGELEN R., Akyuz U., Aydin Y., EREN F., YILMAZ Y.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
, cilt.27, sa.6, ss.667-671, 2015 (SCI-Expanded, Scopus)
2015
2015110. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels
Akyuz U., Yesil A., YILMAZ Y.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
, cilt.50, sa.3, ss.341-346, 2015 (SCI-Expanded)
2015
2015111. Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease
Subasi C. F., Aykut U. E., YILMAZ Y.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
, cilt.27, sa.2, ss.137-141, 2015 (SCI-Expanded)
2014
2014112. No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects
Yonal O., EREN F., YILMAZ Y., ATUĞ Ö., Over H. H.
TURKISH JOURNAL OF GASTROENTEROLOGY
, cilt.25, sa.6, ss.639-643, 2014 (SCI-Expanded, Scopus, TRDizin)
2014
2014113. Can Enhanced Autophagy Be Associated with Human Longevity? Serum Levels of the Autophagy Biomarker Beclin-1 Are Increased in Healthy Centenarians
Emanuele E., Minoretti P., Sanchis-Gomar F., Pareja-Galeano H., YILMAZ Y., Garatachea N., et al.
REJUVENATION RESEARCH
, cilt.17, sa.6, ss.518-524, 2014 (SCI-Expanded)
2014
2014114. Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness.
Sünbül M., Agirbasli M., Durmus E., Kivrak T., Akin H., Aydin Y., et al.
Atherosclerosis
, cilt.237, sa.2, ss.490-3, 2014 (SCI-Expanded)
2014
2014115. A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease
YILMAZ Y., EREN F.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
, cilt.26, sa.11, ss.1292-1295, 2014 (SCI-Expanded, Scopus)
2014
2014116. A comparison of FibroMeter (TM) NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease
Aykut U. E., Akyuz U., Yesil A., EREN F., Gerin F., ERGELEN R., et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
, cilt.49, sa.11, ss.1343-1348, 2014 (SCI-Expanded, Scopus)
2014
2014117. ARE PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE AT INCREASED RISK OF ASTHMA? - RESULTS FROM A TURKISH CROSS-SECTIONAL STUDY
Tasli B., YILMAZ Y.
RESPIROLOGY
, cilt.19, ss.189, 2014 (SCI-Expanded)
2014
2014118. A Potential Treatment of Non-Alcoholic Fatty Liver Disease with SIRT1 Activators
ÇOLAK Y., Yesil A., MUTLU H. H., Caklili O. T., Ulasoglu C., ŞENATEŞ E., et al.
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES
, cilt.23, sa.3, ss.311-319, 2014 (SCI-Expanded)
2014
2014119. Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis
Musso G., Gambino R., Tabibian J. H., Ekstedt M., Kechagias S., Hamaguchi M., et al.
PLOS MEDICINE
, cilt.11, sa.7, 2014 (SCI-Expanded)
2014
2014120. Letter: gut microbiota modulation contributes to coffee's benefits for non-alcoholic fatty liver disease - authors' reply
Yesil A., Yilmaz Y.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
, cilt.39, sa.12, ss.1442, 2014 (SCI-Expanded)
2014
2014121. Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease
YILMAZ Y., Ayyildiz T., Akin H., ÇOLAK Y., Ozturk O., Senates E., et al.
GUT AND LIVER
, cilt.8, sa.3, ss.313-317, 2014 (SCI-Expanded)
2014
2014122. Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy
YILMAZ Y., Yesil A., Gerin F., ERGELEN R., Akin H., ÇELİKEL Ç., et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
, cilt.49, sa.5, ss.611-616, 2014 (SCI-Expanded)
2014
2014123. Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease
YILMAZ Y., Senates E., Yesil A., ERGELEN R., ÇOLAK Y.
JOURNAL OF DIABETES AND ITS COMPLICATIONS
, cilt.28, sa.3, ss.328-331, 2014 (SCI-Expanded)
2014
2014124. Obesity-Associated Nonalcoholic Fatty Liver Disease
YILMAZ Y., Younossi Z. M.
CLINICS IN LIVER DISEASE
, cilt.18, sa.1, ss.19-32, 2014 (SCI-Expanded)
2013
2013125. Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography
YILMAZ Y., ERGELEN R., Akin H., Imeryuz N.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
, cilt.25, sa.11, ss.1330-1334, 2013 (SCI-Expanded)
2013
2013126. Review article: coffee consumption, the metabolic syndrome and non-alcoholic fatty liver disease
Yesil A., Yilmaz Y.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
, cilt.38, sa.9, ss.1038-1044, 2013 (SCI-Expanded)
2013
2013127. Biomarkers for Early Detection of Non-Alcoholic Steatohepatitis: Implications for Drug Development and Clinical Trials
YILMAZ Y.
CURRENT DRUG TARGETS
, cilt.14, sa.11, ss.1357-1366, 2013 (SCI-Expanded)
2013
2013128. Liver disease and malnutrition
Purnak T., YILMAZ Y.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY
, cilt.27, sa.4, ss.619-629, 2013 (SCI-Expanded)
2013
2013129. Assessment of endothelial function in patients with nonalcoholic fatty liver disease
Colak Y., Senates E., Yesil A., YILMAZ Y., Ozturk O., Doganay L., et al.
ENDOCRINE
, cilt.43, sa.1, ss.100-107, 2013 (SCI-Expanded)
2013
2013130. Letter: diagnostic accuracy of M30 levels for identifying patients with non-alcoholic steatohepatitis
Yilmaz Y.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
, cilt.37, sa.2, ss.283, 2013 (SCI-Expanded)
2013
2013131. Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back
YILMAZ Y., ÇOLAK Y., Kurt R., Senates E., EREN F.
TUMORI
, cilt.99, sa.1, ss.10-16, 2013 (SCI-Expanded)
2013
2013132. Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease
YILMAZ Y., Ozturk O., Alandab Y., Senates E., ÇOLAK Y., Doganay H. L., et al.
DIGESTIVE AND LIVER DISEASE
, cilt.45, sa.1, ss.58-62, 2013 (SCI-Expanded, Scopus)
2012
2012133. Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis
YILMAZ Y., EREN F.
CLINICA CHIMICA ACTA
, cilt.414, ss.154-157, 2012 (SCI-Expanded, Scopus)
2012
2012134. Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?
Yılmaz Y.
World Journal of Hepatology
, cilt.4, ss.332-334, 2012 (SCI-Expanded)
2012
2012135. Hepatic expression and serum levels of syndecan 1 (CD 138) in patients with nonalcoholic fatty liver disease
YILMAZ Y., EREN F., ÇOLAK Y., Senates E., ÇELİKEL Ç., Imeryuz N.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
, cilt.47, sa.12, ss.1488-1493, 2012 (SCI-Expanded, Scopus)
2012
2012136. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?
Yilmaz Y.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
, cilt.36, sa.9, ss.815-823, 2012 (SCI-Expanded)
2012
2012137. Research update for articles published in EJCI in 2010
Adlbrecht C., Aigner E., Bellon J. M., Bouloukaki I., Bouzas-Mosquera A., Carrilho A. J. F., et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
, cilt.42, sa.11, ss.1149-1164, 2012 (SCI-Expanded)
2012
2012138. Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease
YILMAZ Y.
CLINICA CHIMICA ACTA
, cilt.413, ss.1190-1193, 2012 (SCI-Expanded)
2012
2012139. Review article: non-alcoholic fatty liver disease and osteoporosis - clinical and molecular crosstalk
Yilmaz Y.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
, cilt.36, sa.4, ss.345-352, 2012 (SCI-Expanded)
2012
2012140. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease
Eren F., Kurt R., Ermis F., Atuğ Ö., Imeryuz N., Yılmaz Y.
Clinical Biochemistry
, cilt.45, ss.655-658, 2012 (SCI-Expanded, Scopus)
2012
2012141. Nonalcoholic Fatty Liver Disease: A Nutritional Approach
ÇOLAK Y., TUNCER İ., Senates E., Ozturk O., Doganay L., YILMAZ Y.
METABOLIC SYNDROME AND RELATED DISORDERS
, cilt.10, sa.3, ss.161-166, 2012 (SCI-Expanded)
2012
2012142. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis
YILMAZ Y., Yonal O., Deyneli O., ÇELİKEL Ç., Kalayci C., DUMAN D.
ACTA GASTRO-ENTEROLOGICA BELGICA
, cilt.75, sa.2, ss.240-244, 2012 (SCI-Expanded)
2012
2012143. Review article: fructose in non-alcoholic fatty liver disease
Yilmaz Y.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
, cilt.35, ss.1135-1144, 2012 (SCI-Expanded)
2012
2012144. Unconjugated hyperbilirubinemia and liver histology in patients with non-alcoholic fatty liver disease
Kurt R., YILMAZ Y.
CLINICAL BIOCHEMISTRY
, cilt.45, sa.6, ss.515, 2012 (SCI-Expanded)
2012
2012145. Circulating vaspin and its relationship with insulin sensitivity, adiponectin and liver histology in subjects with non-alcoholic steatohepatitis
YILMAZ Y.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
, cilt.47, sa.4, ss.489-490, 2012 (SCI-Expanded)
2012
2012146. Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome
YILMAZ Y., Senates E., Ayyildiz T., Colak Y., Tuncer I., Ovunc A. O. K., et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
, cilt.42, sa.4, ss.411-418, 2012 (SCI-Expanded)
2012
2012147. Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology
Colak Y., Senates E., Ozturk O., YILMAZ Y., Zemheri E., Enc F. Y., et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
, cilt.24, sa.3, ss.255-261, 2012 (SCI-Expanded)
2012
2012148. Is M65 really better than M30 as a biomarker of hepatic fibrosis?
YILMAZ Y., Kurt R.
HEPATOLOGY
, cilt.55, sa.2, ss.654, 2012 (SCI-Expanded)
2012
2012149. NAFLD in the Absence of Metabolic Syndrome: Different Epidemiology, Pathogenetic Mechanisms, Risk Factors for Disease Progression?
YILMAZ Y.
SEMINARS IN LIVER DISEASE
, cilt.32, sa.1, ss.14-21, 2012 (SCI-Expanded)
2012
2012150. Preliminary evidence of an association between the functional c-kit rs6554199 polymorphism and achalasia in a Turkish population
Alahdab Y., Eren F., Giral A., Gunduz F., Kedrah A. E., Atug O., et al.
NEUROGASTROENTEROLOGY AND MOTILITY
, cilt.24, sa.1, ss.27-30, 2012 (SCI-Expanded)
2012
2012151. The impact of early percutaneous endoscopic gastrostomy placement on treatment completeness and nutritional status in locally advanced head and neck cancer patients receiving chemoradiotherapy
Atasoy B. M., Yonal O., Demirel B., DANE F., YILMAZ Y., Kalayci C., et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
, cilt.269, sa.1, ss.275-282, 2012 (SCI-Expanded)
2012
2012152. Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: Association with liver fibrosis
ÇOLAK Y., Senates E., Coskunpinar E., Oltulu Y. M., Zemheri E., Ozturk O., et al.
DISEASE MARKERS
, cilt.33, sa.2, ss.77-83, 2012 (SCI-Expanded)
2011
2011153. A Glance at the methods for detection of apoptosis qualitatively and quantitatively Apoptozun nitel ve nicel olarak tespitine yönelik metotlara ki{dotless}sa bir baki{dotless}ş
Ulukaya E., Acilan C., Ari F., Ikitimur E., Yılmaz Y.
Turkish Journal of Biochemistry
, cilt.36, ss.261-269, 2011 (SCI-Expanded)
2011
2011154. Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: Association with ballooning degeneration
YILMAZ Y., Kurt R., EREN F., Imeryuz N.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
, cilt.71, sa.8, ss.631-636, 2011 (SCI-Expanded)
2011
2011155. Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis
YILMAZ Y., EREN F., Ayyildiz T., Colak Y., Kurt R., Senates E., et al.
CLINICA CHIMICA ACTA
, cilt.412, ss.2296-2299, 2011 (SCI-Expanded)
2011
2011156. Cytokeratins in hepatitis
YILMAZ Y.
CLINICA CHIMICA ACTA
, cilt.412, ss.2031-2036, 2011 (SCI-Expanded)
2011
2011157. Plasma Fibrinogen-Like Protein 2 Levels in Patients with Non-Alcoholic Fatty Liver Disease
Colak Y., Senates E., Ozturk O., YILMAZ Y., Coskunpinar E., Kahraman O. T., et al.
HEPATO-GASTROENTEROLOGY
, cilt.58, sa.112, ss.2087-2090, 2011 (SCI-Expanded)
2011
2011158. Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) are higher in ulcerative colitis and correlate with disease activity
Yilmaz Y., Yonal O., Eren F., Atug O., Hamzaoglu H. O.
Journal of Crohn's and Colitis
, cilt.5, sa.5, ss.402-406, 2011 (SCI-Expanded)
2011
2011159. Association Between The Presence of Brown Adipose Tissue and Nonalcoholic Fatty Liver Disease in Adult Humans
Yilmaz Y., Ones T., Purnak T., Kurt R., Ozguven S., Atug O., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
, cilt.38, 2011 (SCI-Expanded)
2011
2011160. A Glance at the methods for detection of apoptosis qualitatively and quantitatively
Ulukaya E., Açılan C., Arı F., Elif İlkay İ., Yılmaz Y.
A Glance at the methods for detection of apoptosis qualitatively and quantitatively
, cilt.36, ss.261-269, 2011 (Hakemli Dergi)
2011
2011161. Serum galectin-3 levels in patients with nonalcoholic fatty liver disease
YILMAZ Y., EREN F., Kurt R., Yonal O., Polat Z., Senates E., et al.
CLINICAL BIOCHEMISTRY
, cilt.44, sa.12, ss.955-958, 2011 (SCI-Expanded, Scopus)
2011
2011162. Association between the presence of brown adipose tissue and non-alcoholic fatty liver disease in adult humans.
Yilmaz Y., Ones T., Purnak T., Ozguven S., Kurt R., Atug O., et al.
Alimentary pharmacology & therapeutics
, cilt.34, sa.3, ss.318-23, 2011 (SCI-Expanded)
2011
2011163. Serum Levels of Hepcidin in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease
Senates E., YILMAZ Y., Colak Y., Ozturk O., Altunoz M. E., Kurt R., et al.
METABOLIC SYNDROME AND RELATED DISORDERS
, cilt.9, sa.4, ss.287-290, 2011 (SCI-Expanded)
2011
2011164. Apoptosis: why and how does it occur in biology?
ULUKAYA E., Acilan C., YILMAZ Y.
CELL BIOCHEMISTRY AND FUNCTION
, cilt.29, sa.6, ss.468-480, 2011 (SCI-Expanded)
2011
2011165. Author's Reply; Noninvasive tests of fibrosis: To get the right answers, we need to ask the right questions
Yılmaz Y., Kurt R.
Hepatitis Monthly
, cilt.11, sa.8, ss.668-670, 2011 (SCI-Expanded)
2011
2011166. Author's Reply; Noninvasive Tests of Fibrosis: To Get the Right Answers, We Need to Ask the Right Questions
YILMAZ Y., Kurt R.
HEPATITIS MONTHLY
, cilt.11, sa.8, ss.669-670, 2011 (SCI-Expanded)
2011
2011167. Multimarker Strategies for Detecting NASH and NASH-Related Fibrosis: Promises and Caveats
YILMAZ Y., Kurt R., EREN F.
OBESITY SURGERY
, cilt.21, sa.8, ss.1316-1317, 2011 (SCI-Expanded)
2011
2011168. Authors' Reply: Noninvasive liver fibrosis assessment; Why does the APRI not work for Hepatitis B?
YILMAZ Y., Yonal O., Kurt R.
HEPATITIS MONTHLY
, cilt.11, sa.7, ss.557, 2011 (SCI-Expanded)
2011
2011169. Reply to Aydin et al: "To what extent is it right to measure serum vaspin, obestatin, and apelin-36 levels without a protease inhibitor in nonalcoholic fatty liver disease?"
Yılmaz Y., Eren F.
Metabolism: Clinical and Experimental
, cilt.60, 2011 (SCI-Expanded)
2011
2011170. Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease
YILMAZ Y., Kurt R., Gurdal A., ÖZEN ALAHDAB Y., Yonal O., Senates E., et al.
ATHEROSCLEROSIS
, cilt.217, sa.1, ss.125-129, 2011 (SCI-Expanded, Scopus)
2011
2011171. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease
Aktas B., YILMAZ Y., EREN F., Yonal O., Kurt R., Alandab Y., et al.
METABOLISM-CLINICAL AND EXPERIMENTAL
, cilt.60, sa.4, ss.544-549, 2011 (SCI-Expanded)
2011
2011172. Kefir Improves the Efficacy and Tolerability of Triple Therapy in Eradicating Helicobacter pylori
Bekar O., YILMAZ Y., Gulten M.
JOURNAL OF MEDICINAL FOOD
, cilt.14, sa.4, ss.344-347, 2011 (SCI-Expanded)
2011
2011173. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease
YILMAZ Y., Yonal O., Kurt R., Bayrak M., Aktas B., Ozdogan O.
HEPATITIS MONTHLY
, cilt.11, sa.2, ss.103-107, 2011 (SCI-Expanded)
2011
2011174. Toward a Biochemical Diagnosis of NASH: Insights From Pathophysiology For Distinguishing Simple Steatosis From Steatohepatitis
Yilmaz Y., Ulukaya E.
CURRENT MEDICINAL CHEMISTRY
, cilt.18, sa.5, ss.725-732, 2011 (SCI-Expanded)
2011
2011175. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease
Yılmaz Y., Yonal O., Kurt R., Alahdab Y., Eren F., Ozdogan O., et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
, cilt.46, sa.1, ss.91-97, 2011 (SCI-Expanded, Scopus)
2011
2011176. Serum progranulin as an independent marker of liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease
Yılmaz Y., Eren F., Yonal O., Polat Z., Bacha M., Kurt R., et al.
Disease Markers
, cilt.31, ss.205-210, 2011 (SCI-Expanded)
2011
2011177. Protective effect of the vasopressin agonist terlipressin in a rat model of contrast-induced nephropathy.
Ari E., Yılmaz Y., Kedrah A. E., Alahdab Y., Cakalagaoglu F., Arikan H., et al.
American journal of nephrology
, cilt.33, sa.3, ss.269-76, 2011 (SCI-Expanded)
2011
2011178. Circulating Levels of Vascular Endothelial Growth Factor A and Its Soluble Receptor in Patients with Biopsy-proven Nonalcoholic Fatty Liver Disease
Yılmaz Y., Yonal O., Kurt R., Alahdab Y., Ozdogan O., Celikel Ç., et al.
ARCHIVES OF MEDICAL RESEARCH
, cilt.42, sa.1, ss.38-43, 2011 (SCI-Expanded)
2011
2011179. Serum zinc-alpha(2)-glycoprotein concentrations in patients with non-alcoholic fatty liver disease
Yılmaz Y., Yonal O., Eren F., Kurt R., Celikel Ç., Ozdogan O., et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
, cilt.49, sa.1, ss.93-97, 2011 (SCI-Expanded)
2010
2010180. Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B
EREN F., YILMAZ Y., Kose S., Ozdemir F. T., Yonal O., Kurt R., et al.
CLINICA CHIMICA ACTA
, cilt.411, ss.2029-2032, 2010 (SCI-Expanded, Scopus)
2010
2010181. Liver Enzymes and Cardiovascular Outcomes a New Research Agenda
YILMAZ Y., Kuri R., Kalayci C.
HEPATOLOGY
, cilt.52, sa.6, ss.2242, 2010 (SCI-Expanded)
2010
2010182. Liver function tests: Association with cardiovascular outcomes
Yılmaz Y.
World Journal of Hepatology
, cilt.2, ss.143-145, 2010 (SCI-Expanded)
2010
2010183. Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease
Yılmaz Y., Yonal O., Kurt R., Oral A. Y., Eren F., Ozdogan O., et al.
Scandinavian Journal of Clinical and Laboratory Investigation
, cilt.70, ss.541-546, 2010 (SCI-Expanded, Scopus)
2010
2010184. Serum fetuin A/alpha 2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis
YILMAZ Y., Yonal O., Kurt R., ARI F., YILMAZTEPE ORAL A., ÇELİKEL Ç., et al.
ANNALS OF CLINICAL BIOCHEMISTRY
, cilt.47, ss.549-553, 2010 (SCI-Expanded)
2010
2010185. Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: zooming in on cytokeratin 18 fragments
YILMAZ Y., Kurt R., Kalayci C.
BIOMARKERS IN MEDICINE
, cilt.4, sa.5, ss.743-745, 2010 (SCI-Expanded)
2010
2010186. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease
Yılmaz Y., Eren F., Yonal O., Kurt R., Aktas B., Çelikel Ç., et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
, cilt.40, sa.10, ss.887-892, 2010 (SCI-Expanded, Scopus)
2010
2010187. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis
YILMAZ Y., Alanhdab Y., Yonal O., Kurt R., Kedrah A. E., ÇELİKEL Ç., et al.
METABOLISM-CLINICAL AND EXPERIMENTAL
, cilt.59, sa.9, ss.1327-1330, 2010 (SCI-Expanded)
2010
2010188. Microalbuminuria and nonalcoholic fatty liver disease
Yılmaz Y., Alahdab Y. O., Yonal O., Imeryuz N., Kalayci C.
Metabolism: Clinical and Experimental
, cilt.59, 2010 (SCI-Expanded)
2010
2010189. Folic Acid and Vitamin B12 Supplementation Improves Coronary Flow Reserve in Elderly Subjects with Vitamin B12 Deficiency
Kurt R., YILMAZ Y., Ermis F., Besisik S. K., Polat N., Elitok A., et al.
ARCHIVES OF MEDICAL RESEARCH
, cilt.41, sa.5, ss.369-372, 2010 (SCI-Expanded)
2010
2010190. Cigarette Smoking Is Not Associated with Specific Histological Features or Severity of Nonalcoholic Fatty Liver Disease
YILMAZ Y., Yonai O., Kurt R., Avsar E.
HEPATOLOGY
, cilt.52, sa.1, ss.391, 2010 (SCI-Expanded)
2010
2010191. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: Association with liver fibrosis
YILMAZ Y., Kurt R., Yonal O., Polat N., ÇELİKEL Ç., Gurdal A., et al.
ATHEROSCLEROSIS
, cilt.211, sa.1, ss.182-186, 2010 (SCI-Expanded)
2010
2010192. The AGEs-RAGE axis and nonalcoholic steatohepatitis: the evidence mounts
Yilmaz Y.
JOURNAL OF GASTROENTEROLOGY
, cilt.45, sa.7, ss.782-783, 2010 (SCI-Expanded)
2010
2010193. C-KIT Gene Polymorphism in Achalasia
Alahdab Y. O., EREN F., Gunduz F., Kedrah A. E., YILMAZ Y., Atug O., et al.
GASTROENTEROLOGY
, cilt.138, sa.5, 2010 (SCI-Expanded)
2010
2010194. The Impact of Prophylactic Percutaneus Endoscopic Gastrostomy to Nutritional Status and Quality of Life in Locally Advanced Head and Neck Cancer Patients Receiving Chemoradiotherapy
Yonal O., Atasoy B. M., Demirel B., YILMAZ Y., Dane F., ABACIOGLU M. U., et al.
GASTROENTEROLOGY
, cilt.138, sa.5, 2010 (SCI-Expanded)
2010
2010195. Microalbuminuria in Nondiabetic Patients With Nonalcoholic Fatty Liver Disease: Association With Liver Fibrosis
YILMAZ Y., Alahdab Y. O., Yonal O., Kurt R., Kedrah A. E., Celikel Ç., et al.
GASTROENTEROLOGY
, cilt.138, sa.5, 2010 (SCI-Expanded)
2010
2010196. Molecular Signatures of Nonalcoholic Fatty Liver Disease: The Present and Future
YILMAZ Y., ULUKAYA E.
HEPATOLOGY
, cilt.51, sa.5, ss.1866, 2010 (SCI-Expanded)
2010
2010197. Plasma prohepcidin levels in patients with chronic viral hepatitis: relationship with liver fibrosis
Olmez O. F., Gurel S., YILMAZ Y.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
, cilt.22, sa.4, ss.461-465, 2010 (SCI-Expanded)
2010
2010198. M30 levels and nonalcoholic steatohepatitis in polycystic ovary syndrome
Yılmaz Y., Kurt R.
Journal Of Clinical Endocrinology , cilt.0, sa.0, 2010 (SCI-Expanded)
2010
2010199. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients
Gul O. O., Tuncel E., YILMAZ Y., ULUKAYA E., Gul C. B., Kiyici S., et al.
METABOLISM-CLINICAL AND EXPERIMENTAL
, cilt.59, sa.1, ss.64-69, 2010 (SCI-Expanded)
2009
2009200. Serial changes in circulating M30 antigen, a biomarker of apoptosis, in patients with acute coronary syndromes: Relationship with the severity of coronary artery disease
Senturk T., Aydinlar A., Yilmaz Y., Yilmaztepe Oral A., Ozdabakoglu O., Ulukaya E.
Coronary Artery Disease
, cilt.20, ss.494-498, 2009 (SCI-Expanded)
2009
2009201. Systematic review: Caspase-cleaved fragments of cytokeratin 18 - The promises and challenges of a biomarker for chronic liver disease
Yılmaz Y.
Alimentary Pharmacology and Therapeutics
, cilt.30, ss.1103-1109, 2009 (SCI-Expanded)
2009
2009202. Familial Mediterranean Fever coexisting with celiac disease: Is there a link with long-term colchicine treatment?
Yilmaz Y., Baran B., Seniz N. B., Dolar E.
Journal of Gastrointestinal and Liver Diseases
, cilt.18, ss.119-120, 2009 (SCI-Expanded)
2009
2009203. Metformin, hepatitis C, and insulin resistance: Sufficient evidence?
Yılmaz Y., Yonal O., Imeryuz N.
Hepatology
, cilt.50, ss.2054-2055, 2009 (SCI-Expanded)
2009
2009204. Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: Association with insulin resistance
Yılmaz Y., Ulukaya E., Atuğ Ö., Dolar E.
European Journal of Gastroenterology and Hepatology
, cilt.21, ss.1247-1251, 2009 (SCI-Expanded)
2009
2009205. Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients
Arabul M., Gullulu M., Yilmaz Y., Eren M. A., Baran B., Gul C. B., et al.
Medical Science Monitor
, cilt.15, 2009 (SCI-Expanded)
2009
2009206. Non-alcoholic fatty liver disease and microalbuminuria in non-diabetic patients: Role of insulin resistance
Yılmaz Y., Alahdab Y., Özdoğan O. C., Dolar E.
Internal Medicine Journal
, cilt.39, ss.709-710, 2009 (SCI-Expanded)
2009
2009207. Human serum complement C3 and factor H in the syndrome of hemolysis, elevated liver enzymes, and low platelet count.
Ari E., YILMAZ Y., Gul A., ÖZEN ALAHDAB Y., Kedrah A. E., Macunluoglu B., et al.
American journal of reproductive immunology (New York, N.Y. : 1989)
, cilt.62, sa.4, ss.238-42, 2009 (SCI-Expanded)
2009
2009208. Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis.
YILMAZ Y., Kedrah A. E., Ozdogan O. C.
World journal of gastroenterology
, cilt.15, sa.35, ss.4387-91, 2009 (SCI-Expanded)
2009
2009209. Biomarkers for noninvasive biochemical diagnosis of nonalcoholic steatohepatitis: Tools or decorations?
YILMAZ Y., Dolar E.
WORLD JOURNAL OF GASTROENTEROLOGY
, cilt.15, sa.34, ss.4346-4347, 2009 (SCI-Expanded)
2009
2009210. "Defragmenting" the Noninvasive Diagnosis of Nonalcoholic Steatohepatitis: Hopes from Cytokeratin-18
Yilmaz Y.
HEPATOLOGY
, cilt.50, sa.3, ss.990-991, 2009 (SCI-Expanded)
2009
2009211. Commentary on "Cytokeratin 18, a Marker of Cell Death, is Increased in Children With Suspected Nonalcoholic Fatty Liver Disease"
YILMAZ Y., Dolar E., ULUKAYA E.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
, cilt.49, sa.3, ss.371, 2009 (SCI-Expanded)
2009
2009212. The quest for liver fibrosis biomarkers: Promises from the enhanced liver fibrosis panel and beyond
Yilmaz Y., Ulukaya E., Dolar E.
Hepatology
, cilt.49, ss.1056-1057, 2009 (SCI-Expanded)
2009
2009213. Serum M30 levels: A potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels
Yilmaz Y., Ulukaya E., Dolar E.
Hepatology
, cilt.49, ss.697, 2009 (SCI-Expanded)
2009
2009214. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease
YILMAZ Y., ULUKAYA E., Gul O. O., Arabul M., Gul C. B., ATUĞ Ö., et al.
CLINICAL BIOCHEMISTRY
, cilt.42, sa.9, ss.802-807, 2009 (SCI-Expanded)
2009
2009215. Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C
Yilmaz Y., Dolar E., Ulukaya E., Akgoz S., Keskin M., Kiyici M., et al.
Medical Science Monitor
, cilt.15, 2009 (SCI-Expanded)
2009
2009216. Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C
ATUĞ Ö., Akin H., YILMAZ Y., Sari M., Tozun N.
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES
, cilt.18, sa.2, ss.256, 2009 (SCI-Expanded)
2009
2009217. Coronary artery anomalies in patients with syndrome X
Akgüllü Ç., Yilmaz Y., Yücel E., Kaderli A. A., Kumbay E., Ayndinlar A.
Anadolu Kardiyoloji Dergisi
, cilt.9, ss.69, 2009 (SCI-Expanded)
2009
2009218. Serum Levels of Adipokines in Patients with Chronic HCV Infection: Relationship with Steatosis and Fibrosis
Tiftikci A., ATUĞ Ö., YILMAZ Y., EREN F., Ozdemir F. T., Yapali S., et al.
ARCHIVES OF MEDICAL RESEARCH
, cilt.40, sa.4, ss.294-298, 2009 (SCI-Expanded)
2009
2009219. Baseline and salt-stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: Relation to disease severity
Keskin M., Dolar E., Dirican M., Kiyici M., Yilmaz Y., Gurel S., et al.
Internal Medicine Journal
, cilt.39, ss.243-248, 2009 (SCI-Expanded)
2009
2009220. Dipeptidyl peptidase IV inhibitors: Therapeutic potential in nonalcoholic fatty liver disease
YILMAZ Y., ATUĞ Ö., Yonal O., DUMAN D., Ozdogan O., Imeryuz N., et al.
MEDICAL SCIENCE MONITOR
, cilt.15, sa.4, 2009 (SCI-Expanded)
2009
2009221. Liver Disease as a Risk Factor for Cognitive Decline and Dementia: an Under-Recognized Issue
YILMAZ Y., Ozdogan O.
HEPATOLOGY
, cilt.49, sa.2, ss.698, 2009 (SCI-Expanded)
2009
2009222. Small arterial elasticity predicts the extent of coronary artery disease: Relationship with serum uric acid
Fazlioǧlu M., Şentürk T., Kumbay E., Kaderli A. A., Yilmaz Y., Özdemir B., et al.
Atherosclerosis
, cilt.202, ss.200-204, 2009 (SCI-Expanded)
2009
2009223. Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry
ULUKAYA E., YILMAZ Y., Moshkovskii S., Karpova M., Pyatnitskiy M., ATUĞ Ö., et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
, cilt.44, sa.12, ss.1471-1476, 2009 (SCI-Expanded)
2009
2009224. Acute arsenic self-poisoning for suicidal purpose in a dentist: A case report
Yilmaz Y., Armagan E., Olmez O., Esen M., Alkis N., Dolar E.
Human and Experimental Toxicology
, cilt.28, ss.63-65, 2009 (SCI-Expanded)
2008
2008225. Concomitant colitis in a patient with Behcet's disease
Yilmaz Y., Dolar E.
Journal of Gastrointestinal and Liver Diseases
, cilt.17, sa.4, ss.481-483, 2008 (SCI-Expanded)
2008
2008226. Predictive value of the modified early warning score in a turkish emergency department
Armagan E., Yilmaz Y., Olmez O. F., Simsek G., Gul C. B.
European Journal of Emergency Medicine
, cilt.15, ss.338-340, 2008 (SCI-Expanded)
2008
2008227. A "biomarker biopsy" for the diagnosis of NASH: Promises from CK-18 fragments
Yilmaz Y., Ulukaya E., Dolar E.
Obesity Surgery
, cilt.18, ss.1507-1508, 2008 (SCI-Expanded)
2008
2008228. Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease
Arabul M., Gullulu M., Yilmaz Y., Akdag I., Kahvecioglu S., Ali Eren M., et al.
Clinical Biochemistry
, cilt.41, ss.1055-1058, 2008 (SCI-Expanded)
2008
2008229. Effect of intensive statin therapy on arterial elasticity in patients with coronary artery disease
Akgullu C., Ozdemir B., Yilmaz Y., Kazazoglu A. R., Aydinlar A.
Acta Cardiologica
, cilt.63, sa.4, ss.467-471, 2008 (SCI-Expanded)
2008
2008230. The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-γ2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease
Catalano M., Cortelazzo A., Santi R., Contino L., Demicheli M., Yilmaz Y., et al.
Clinical Biochemistry
, cilt.41, ss.981-985, 2008 (SCI-Expanded)
2008
2008231. Helicobacter pylori: A role in schizophrenia?
Yilmaz Y., Gul C. B., Arabul M., Eren M. A.
Medical Science Monitor
, cilt.14, 2008 (SCI-Expanded)
2008
2008232. Apical ballooning syndrome: A metabolic form of cardiomyopathy?
Yilmaz Y.
Medical Science Monitor
, cilt.14, 2008 (SCI-Expanded)
2008
2008233. Urinary IL-18: A marker of contrast-induced nephropathy following percutaneous coronary intervention?
Bulent Gul C., Gullulu M., Oral B., Aydinlar A., Oz O., Budak F., et al.
Clinical Biochemistry
, cilt.41, ss.544-547, 2008 (SCI-Expanded)
2008
2008234. Acute myocardial infarction, ischemic cerebrovascular disease and variceal bleeding due to portal vein thrombosis in a patient with hereditary thrombophilia
Baran B., Yilmaz Y., Algin O., Keskin M., Kiyici M., Kocamaz G., et al.
Blood Coagulation and Fibrinolysis
, cilt.19, ss.243-246, 2008 (SCI-Expanded)
2008
2008235. The -374T/A RAGE Polymorphism Protects Against Future Cardiac Events in Nondiabetic Patients with Coronary Artery Disease
Falcone C., Geroldi D., Buzzi M. P., Emanuele E., Yilmaz Y., Fontana J. M., et al.
Archives of Medical Research
, cilt.39, ss.320-325, 2008 (SCI-Expanded)
2008
2008236. Psychopathology in the context of obesity: The adiponectin hypothesis
Yilmaz Y.
Medical Hypotheses
, cilt.70, ss.902-903, 2008 (SCI-Expanded)
2008
2008237. Clinical value of the malnutrition-inflammation-atherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: A 5-year prospective study
Akdag I., Yilmaz Y., Kahvecioglu S., Bolca N., Ercan I., Ersoy A., et al.
Nephron - Clinical Practice
, cilt.108, 2008 (SCI-Expanded)
2008
2008238. The LPA gene C93T polymorphism influences plasma lipoprotein(a) levels and is independently associated with susceptibility to peripheral arterial disease
Catalano M., Cortelazzo A., Yilmaz Y., Perilli E., Carzaniga G., Emanuele E.
Clinica Chimica Acta
, cilt.387, ss.109-112, 2008 (SCI-Expanded)
2007
2007239. Evaluation of leukocyte esterase and nitrite strip tests to detect spontaneous bacterial peritonitis in cirrhotic patients
Torun S., Dolar E., Yilmaz Y., Keskin M., Kiyici M., Sinirtas M., et al.
World Journal of Gastroenterology
, cilt.13, ss.6027-6030, 2007 (SCI-Expanded)
2007
2007240. Clinical significance of activity of ALT enzyme in patients with hepatitis C virus
Akkaya O., Kiyici M., Yilmaz Y., Ulukaya E., Yerci O.
World Journal of Gastroenterology
, cilt.13, ss.5481-5485, 2007 (SCI-Expanded)
2007
2007241. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis
Yilmaz Y., Dolar E., Ulukaya E., Akgoz S., Keskin M., Kiyici M., et al.
World Journal of Gastroenterology
, cilt.13, ss.837-844, 2007 (SCI-Expanded)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2021
20211. ANALYSIS OF THE EFFICACY OF A HIGHER DAILY ARAMCHOL DOSE ON FIBROSIS IMPROVEMENT IN THE ARMOR STUDY OPEN LABEL PART
Gorfine T., Ratziu V., YILMAZ Y., Friedman S. L., Hayardeny L., Kadosh S., et al.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 12 Kasım 2021, (Tam Metin Bildiri)
2021
20212. Development and validation of Agile 4 and Agile 3+: Novel FibroScan based scores for the diagnosis of cirrhosis and advanced fibrosis in patients with non-alcoholic fatty liver disease
YILMAZ Y.
French Hepatology congress (AFEF) 29 Eylül 2021-02 Ekim 2021, Biarritz, Fransa, 07 Temmuz 2021, (Tam Metin Bildiri)
2021
20213. The global non-alcoholic fatty liver disease (NAFLD) preparedness index: are countries ready to tackle the challenge?
Lazarus J., Mark H., Palayew A., Patrizia C., Colombo M., Ekstedt M., et al.
International Liver Congress, ELECTR NETWORK, 23 - 26 Haziran 2021, cilt.75, (Özet Bildiri)
2021
20214. The Impact of COVID-19 Pandemic on Patients with Chronic Liver Disease (CLD): Data from the Global Registry
YOUNOSSI Z. M., YILMAZ Y., El Kassas M., Duseja A. K., Saeed H., Gammal E., et al.
International Liver Congress (EASL), Roma, İtalya, 23 Haziran 2021, cilt.75, ss.655, (Tam Metin Bildiri)
2021
20215. Individual patient data meta-analysis of the diagnostic performance of single and sequentially combined non-invasive tests in detecting advanced fibrosis
YILMAZ Y.
International Liver Congress (EASL), Roma, İtalya, 23 Haziran 2021, cilt.75, ss.259-260, (Tam Metin Bildiri)
2021
20216. Development and validation of Agile 3+: novel FibroScan based score for the diagnosis of advanced fibrosis in patients with nonalcoholic fatty liver disease
YOUNOSSI Z. M., Harrison S. A., Newsome P. N., CHAN W. K., YILMAZ Y., Ledinghen V. d., et al.
International Liver Congress (EASL), Roma, İtalya, 23 - 26 Haziran 2021, cilt.75, ss.257, (Tam Metin Bildiri)
2021
20217. A GLOBAL SURVEY OF PHYSICIANS KNOWLEDGE ABOUT NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
YILMAZ Y.
Digestive Disease Week, Amerika Birleşik Devletleri, 21 Mayıs 2021, cilt.160, ss.830, (Tam Metin Bildiri)
2021
20218. CLINICAL PRESENTATION OF LEAN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) ACROSS THE WORLD: DATA FROM THE GLOBAL NASH REGISTRY
YILMAZ Y.
Digestive Disease Week, Amerika Birleşik Devletleri, 21 Mayıs 2021, cilt.160, ss.771-772, (Tam Metin Bildiri)
2021
20219. CLINICAL PRESENTATION AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC VIRAL HEPATITIS: DATA FROM THE GLOBAL LIVER REGISTRY (TM)
YILMAZ Y.
Digestive Disease Week, Amerika Birleşik Devletleri, 21 Mayıs 2021, cilt.160, ss.821-822, (Tam Metin Bildiri)
2020
202010. THE IMPACT OF CHRONIC HEPATITIS B ON PATIENT-REPORTED OUTCOMES FROM THE GLOBAL LIVER REGISTRY (TM)
YILMAZ Y., Yu M., Lam B. P., Ferret M. A. B., Papatheodoridis G., Chan W. K., et al.
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72, (Özet Bildiri)
2020
202011. SIGNIFICANT KNOWLEDGE GAP ABOUT NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN REAL-WORLD PRACTICES: A GLOBAL SURVEY OF HEPATOLOGISTS, GASTROENTEROLOGISTS, ENDOCRINOLOGISTS AND PRIMARY CARE PHYSICIANS
Younossi Z. M., Takahashi H., Eguchi Y., YILMAZ Y., El Kassas M., Zheng M., et al.
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72, (Özet Bildiri)
2020
202012. CLINICAL AND PATIENT-REPORTED OUTCOMES DATA OF NON-ALCOHOLIC FATTY LIVER DISEASE: LONGITUDINAL DATA FROM THE GLOBAL NASH REGISTRY (TM)
Younossi Z. M., YILMAZ Y., Yu M., Wong V. W., Castellanos Fernandez M., Isakov V. A., et al.
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72, (Özet Bildiri)
2020
202013. PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C: DATA FROM THE GLOBAL LIVER REGISTRY (TM)
Yu M., El Kassas M., Lam B. P., Esmat G., Femandez M. C., Ferret M. A. B., et al.
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72, (Özet Bildiri)
2020
202014. Comparison of clinical and histological characteristics of biopsyproven non-alcoholic fatty liver patients with and without type 2 diabetes mellitus: 10 years of experience from a single tertiary care center
YILMAZ Y.
APASL 2020 Bali - 29th Annual Conference Asian Pacific Association for the Study of the Liver, Balvi, Letonya, 4 - 08 Mart 2020, cilt.14, ss.1-470, (Özet Bildiri)
2020
202015. THE IMPACT OF FATIGUE ON PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY (GLR)
YILMAZ Y.
Digestive Disease Week, Amerika Birleşik Devletleri, 23 Ocak 2020, cilt.158, ss.1269, (Tam Metin Bildiri)
2019
201916. ARTERIAL STIFFNESS IS INDEPENDENTLY ASSOCIATED WITH LIVER STIFFNESS IN BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE: A TRANSIENT ELASTOGRAPHY STUDY
YILMAZ Y.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 08 Kasım 2019, cilt.70, ss.1063-1064, (Tam Metin Bildiri)
2019
201917. CAN ADVANCED FIBROSIS RELIABLY EXCLUDED BY SIMPLE NON-INVASIVE FIBROSIS SCORING SYSTEMS?: PERFORMANCE OF FIB-4 AND NFS IN A BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE SAMPLE
YILMAZ Y.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 08 Kasım 2019, cilt.70, ss.1053-1054, (Tam Metin Bildiri)
2019
201918. SEVERE IMPAIRMENT OF PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION SEEN IN REAL-WORLD PRACTICES ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY
YILMAZ Y.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 08 Kasım 2019, cilt.359, (Tam Metin Bildiri)
2019
201919. CLINICAL AND PATIENT-REPORTED OUTCOMES DATA FOR PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON-ALCOHOLIC STEATOHEPATITIS (NASH) ACROSS THE WORLD: DATA FROM THE GLOBAL NASH REGISTRY
YILMAZ Y.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 08 Kasım 2019, (Tam Metin Bildiri)
2019
201920. DIFFERENCES IN THE CLINICAL PROFILE OF THE MOST COMMON CAUSES OF CHRONIC LIVER DISEASE (CLD) ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY.
YILMAZ Y.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 08 Kasım 2019, cilt.70, ss.463-465, (Tam Metin Bildiri)
2019
201921. CLINICAL AND PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS (HBV) INFECTION SEEN IN REAL-WORLD PRACTICES ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY
YILMAZ Y.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 08 Kasım 2019, cilt.70, ss.577-578, (Tam Metin Bildiri)
2019
201922. USEFULNESS OF ENDOSCOPIC ULTRASONOGRAPHY ELASTOGRAPHY (EUS-E) TO MEASURE LIVER STIFFNESS
Duman D. G., Alahdab Y., Demirtas C. O., YILMAZ Y., GÜNDÜZ F.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri)
2019
201923. THE UTILITY OF NONINVASIVE SCORES IN ASSESSING THE ADVANCED HEPATIC FIBROSIS IN TYPE 2 DIABETIC PATIENTS WITH BIOPSY PROVEN NONALCOHOLIC FATTY LIVER DISEASE
Alkayyali T., Quatranji L., Kaya E., Bakir A., YILMAZ Y.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri)
2019
201924. ARTERIAL STIFFNESS IS INDEPENDENTLY ASSOCIATED WITH LIVER STIFFNESS IN BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE: A TRANSIENT ELASTOGRAPHY STUDY
Bilgin B. O., SÜNBÜL M., Kani H. T., Demirtas C. O., KEKLİKKIRAN Ç., YILMAZ Y.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri)
2019
201925. lLver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease
Sun D., Fun Zhou Y., Kani H. T., Chen Fei Z., Pei Wu Z., Hong Lei M., et al.
EASL 2019, Paris, Fransa, 14 Nisan 2019, (Özet Bildiri)
2019
201926. ILver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease
Sun D. Q., Ye F., Haluk Tarik K., Zheng C., Zhu P., Ma H., et al.
International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Avusturya, 10 - 14 Nisan 2019, cilt.70, (Özet Bildiri)
2019
201927. Translating NAFLD AASLD data to local practice
YILMAZ Y.
AASLD TASL Regional Connect Meeting, İstanbul, Türkiye, 15 - 16 Mart 2019, (Özet Bildiri)
2018
201828. Nonalcoholic Fatty Liver Disease(NAFLD) and Alcoholic Fatty Lİver Disease(AFLD): The impact of Alcohol Comsumpt,on and Metabolic Syndrome on Mortality
Younossi Z., Stepanova M., Ong J., Yılmaz Y., Duseja A., Eguchi Y., et al.
THE AASLD LIVER MEETING, South-Carolina, Amerika Birleşik Devletleri, 9 - 13 Kasım 2018, (Özet Bildiri)
2018
201829. Noninvazif Fibrozis ve Yağlanma Ölçümü:Fibroscan/CAP
YILMAZ Y.
4. Azerbaycan-Türkiye Ortak Hepatoloji Kursu, Baku, Azerbaycan, 06 Ekim 2018, (Özet Bildiri)
2018
201830. Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcoholic Fatty Liver Disease (AFLD): The Impact of Alcohol Consumption and Metabolic Syndrome on Mortality
Younossi Z. M., Stepanova M., Ong J., YILMAZ Y., Duseja A. K., Eguchi Y., et al.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Kostarika, 9 - 13 Kasım 2018, cilt.68, (Özet Bildiri)
2018
201831. Non-alcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma listed for liver transplantation in United States: data from the Scientific Registry of Transplant Recipients
Younossi Z., Stepanova M., Ong J., Jacobson I., Bugianesi E., Duseja A., et al.
Joint International Congress of ILTS, ELITA and LICAGE, Lisbon, Portekiz, 23 - 26 Mayıs 2018, cilt.102, ss.304-305, (Özet Bildiri)
2018
201832. Transient elastography with controlled attenuation parameterin the assessment of hepatic steatosis and significant liver fibrosisin patients with scleroderma
Yılmaz Y., Kani H. T., Şahinkaya Y., Mursaloğlu H. H., Aziziy M., İnanç G. N., et al.
27th Annual Conference of APASL, Dilli, Hindistan, 14 - 18 Mart 2018, cilt.12, ss.378, (Özet Bildiri)
2018
201833. Karaciğer fibrozisinin değerlendirilmesinde elastografinin rolü
YILMAZ Y.
Baku 2018 Hepatoloji Sempozyumu, Baku, Azerbaycan, 21 Ocak 2018, (Özet Bildiri)
2018
201834. Klinik pratikte transiyent elastografi kullanımı
YILMAZ Y.
Baku 2018 Hepatoloji Sempozyumu, Baku, Azerbaycan, 21 Ocak 2018, (Özet Bildiri)
2018
201835. Tanıdan tedaviye alkole bağlı olmayan yağlı karaciğer hastalığı
YILMAZ Y.
Baku 2018 Hepatoloji Sempozyumu, Baku, Azerbaycan, 21 Ocak 2018, (Özet Bildiri)
2017
201736. Preliminary evidence of an association between mtDNA D-loop polymorphisms and the clinicopathological features of nonalcoholic steatohepatitis
Hasturk B., Yılmaz Y., Eren F.
68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Washington, Kiribati, 20 - 24 Ekim 2017, cilt.66, (Özet Bildiri)
2017
201737. Nonalcoholic steatohepatitis: modulation of histological phenotype by the missense Thr174Met (rs4762) polymorphism of the angiotensinogen (AGT) gene
EREN F., Balcilar H., Yilmaz D., Toker T., YILMAZ Y., Hasturk B.
68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Washington, Kiribati, 20 - 24 Ekim 2017, cilt.66, (Özet Bildiri)
2017
201738. Mitochondrial DNA control region nucleotide variations in non-alcoholic steatohepatitis
Hasturk B., Yılmaz Y., Eren F.
European Biotechnology Congress, Dubrovnik, Hırvatistan, 25 - 27 Mayıs 2017, cilt.256, (Özet Bildiri)
2017
201739. Prevalence of fatty liver in inflammatory bowel disease : a transient elastography study on the basis of a controlled attenuation parameter.
YILMAZ Y., KANİ H. T.
5th Annual Meeting of the Asian Organization for Crohn’s and Colitis, Seul, Güney Kore, 15 - 17 Haziran 2017, (Özet Bildiri)
2017
201740. Prevalence of Fatty Liver in IBD: ATransient Elastography Study on theBasis of a Controlled AttenuationParameter
Kani H. T., Demirtas I., Yılmaz Y.
The 5th Annual Meeting of Asian Organization for Crohn’s Colitis, Seoul, Güney Kore, 15 - 17 Haziran 2017, ss.235-236, (Özet Bildiri)
2017
201741. NAFLD: Yeni ne var?
YILMAZ Y.
11. Ulusal Hepatoloji Kongresi, Antalya, Türkiye, 17 - 21 Mayıs 2017, (Özet Bildiri)
2017
201742. Hepatit C Tedavilerinin İlaç Etkileşimleri
YILMAZ Y.
Sağlık Bilimleri Üniversitesi Gastroenteroloji Günleri, İstanbul, Türkiye, 28 - 29 Nisan 2017, (Özet Bildiri)
2017
201743. Marmara Üniversitesi Tıp Fakültesi Harvoni Deneyimi
YILMAZ Y.
Sağlık Bilimleri Üniversitesi Gastroenteroloji Günleri, İstanbul, Türkiye, 28 - 29 Nisan 2017, (Özet Bildiri)
2017
201744. NASH'te yeni ne var?
YILMAZ Y.
14. Ulusal Hepatogastroenteroloji Kongresi, Antalya, Türkiye, 5 - 08 Nisan 2017, (Özet Bildiri)
2016
201645. Yüzyılın Epidemisi Alkol Dışı Karaciğer Yağlanması Hastalığı
YILMAZ Y.
33. Ulusal Gastroenteroloji Haftası, Antalya, Türkiye, 22 - 27 Aralık 2016
2016
201646. COMPARİSİON OF DOPPLER ULTRASOUND AND TRANSİENT ELASTOGRAPHY FOR DİAGNOSİS OF SİGNİFİCANT FİBROSİS İN NONALCOHOLİC STEATOHEPATİT
ERGELEN R., YILMAZ Y., ASADOV R., CELİKEL Ç., AKIN H., BUGDAYCI O., et al.
ESGAR, 14 - 16 Aralık 2016, (Özet Bildiri)
2016
201647. Obezite ve yağlı karaciğer
YILMAZ Y.
7. Ulusal Obezite Kongresi, İstanbul, Türkiye, 8 - 11 Aralık 2016
2016
201648. Sülfasalazin kullanımı sonrası gelişen Dress sendromu Olgu sunumu
DURĞAY M., AYKUT U. E., ÖZEN ALAHDAB Y., YILMAZ Y., DEMİR O.
33. Ulusal Gastroenteroloji Haftası, Antalya, Türkiye, 22 - 27 Kasım 2016, (Özet Bildiri)
2016
201649. Türk toplumunda alkolik olmayan yağlı karaciğer hastalığının genetik polimorfizm ile ilişkisi çok merkezli kontrollü çalışma
UYGUN A., öztürk k., DEMİRCİ H., öztuna a., EREN F., YILMAZ Y., et al.
33.Ulusal gastronetroloji haftası, Antalya, Türkiye, 22 - 27 Kasım 2016, (Özet Bildiri)
2016
201650. İrritabl barsak sendromlu hastalarda yüksek laktoz intolerans sıklığı
hasanov r., ÖZEN ALAHDAB Y., EREN F., GÜNDÜZ F., YILMAZ Y., AYKUT U. E.
33.Ulusal gastroenetroloji haftası, Türkiye, 22 - 27 Kasım 2016, (Özet Bildiri)
2016
201651. Two atypical forms of Nonalcoholic fatty liver disease NAFLD without metabolic syndrome and Lean NAFLD
YILMAZ Y.
APASL Single Topic Conference, İstanbul, Türkiye, 22 - 24 Eylül 2016, (Tam Metin Bildiri)
2016
201652. Bactericidal permeability increasing protein has no effect on remission of ulcerative colitis
EREN F., eroğlu k., Banzragch M., GÜNDÜZ F., ÖZEN ALAHDAB Y., KURT R., et al.
The 4th Annual Meeting of Asian Organization for Crohn's & Colitis, Kyoto, Japonya, 7 - 09 Temmuz 2016
2016
201653. MT ND5 gene variants have both protective and risk factor for inflammatory bowel disease
Eren F., Safarova C., Gündüz F., Özen Alahdab Y., Kurt R., Yılmaz Y., et al.
The 4th Annual Meeting of Asian Organization for Crohn's & Colitis, Kyoto, Japonya, 7 - 09 Temmuz 2016, (Özet Bildiri)
2016
201654. Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis
ERGELEN R., YILMAZ Y., ASADOV R., ÇELİKEL Ç., AKIN H., BUGDAYCI O., et al.
European Society of Gastrointestinal and Abdominal Radiology, 14 - 17 Haziran 2016
2016
201655. Yağlı Karaciğerde Yeni İlaç Tedavileri
YILMAZ Y.
Klinik Gastroenteroloji Toplantısı-5, İstanbul, Türkiye, 02 Haziran 2016
2016
201656. Kronik Viral Hepatitlerde Non İnvazif Yöntemle Fibrozis Belirleme Algoritmleri
YILMAZ Y.
Hepatit B Enfeksiyonu Akademisi, Çanakkale, Türkiye, 28 Mayıs 2016
2016
201657. Controlled attenuation parameter and liver stiffness measurements by fibroscan for the detection of non alcoholic fatty liver disease in patients with type 2 diabetes results from a pilot study
DURĞAY M., DEYNELİ O., YILMAZ Y.
EASL monothematic conference 2016, Riga, Letonya, 12 - 14 Mayıs 2016, (Özet Bildiri)
2016
201658. Karaciğer Hasarının Değerlendirilmesi Non İnvazif Testlere Algoritmik Yaklaşım
YILMAZ Y.
XIII. Ulusal Viral Hepatit Kongresi, Antalya, Türkiye, 17 - 20 Mart 2016
2016
201659. Alkol Dışı Yağlı Karaciğer Hastalığında Yeni Ne Var
YILMAZ Y.
TKAD Mezuniyet Sonrası Eğitim Sempozyumu: Karaciğerde Çok Yenilik Var:AASLD 2015’den Süzülenler, İstanbul, Türkiye, 13 Ocak 2016
2015
201560. Karaciğer Fibrozisinde Yeni Non İnvaziv Yöntem ELF Test
DURUSOY S. S., ÖZDEMİR F. T., ÖZDOĞAN O. C., RAHMİ A., YILMAZ Y., YEĞİN E. G., et al.
32. Ulusal Gastroenteroloji Haftası, Türkiye, 25 - 29 Kasım 2015
2015
201561. Does Helicobacter pylori Infection Influences the Complication rate After Sleeve Gastrectomy From an Endemic Region
AKYÜZ Ü., ALTUN H., BURÇİN B., YILMAZ Y., DERYA U.
32. Ulusal Gastroenteroloji Haftası, Türkiye, 25 - 29 Kasım 2015
2015
201562. Ülseratif Kolitin ÜK Hastalık Aktivitesi Bakterisidal Permeabilite Arttırıcı Protein BPI Düzeyi ile İlişkilidir
EREN F., EROĞLU K., MUNKHTSETSEG B., ALAHDAB Y. Ö., KURT R., YILMAZ Y., et al.
32. Ulusal Gastroenteroloji Haftası, Türkiye, 25 - 29 Kasım 2015
2015
201563. NASH Pategenez ve Tedavisinde Yeni Bir Şey Var Mı
YILMAZ Y.
32.Ulusal Gastroenteroloji Haftası, Antalya, Türkiye, 25 - 29 Kasım 2015
2015
201564. Diyabetik Hastalarda Nonalkolik Yağlı Karaciğer Hastalığının ve Fibrozisin Fibroscan Aracılı CAP ve Karaciğer Sertlik Ölçümü ile Prospektif Taranması Ön Bulgularımız
DURĞAY M., DEYNELİ O., YILMAZ Y.
32. Ulusal Gastroenteroloji Haftası, Türkiye, 25 - 29 Kasım 2015
2015
201565. Ülseratif kolitin hastalık aktivitesi bakterisidal permeabilite arttırıcı protein BPI düzeyi ile ilişkilidir
EREN F., eroğlu k., banzragch m., GÜNDÜZ F., ÖZEN ALAHDAB Y., KURT R., et al.
32. Ulusal Gastroenetroloji Haftası, Türkiye, 25 - 29 Kasım 2015
2015
201566. NAFLD in absence of Metabolic Syndrome
YILMAZ Y.
FRONTIERS IN HEPATOLOGY Non-alcoholic Fatty Liver Disease & the Metabolic Syndrome – Key questions on disease consequences and treatment –, Londrina, Brezilya, 24 Kasım 2015, (Tam Metin Bildiri)
2015
201567. Latent tüberküloz tanısında interferon gamma salınım testi ile tüberkülin deri testinin karşılaştırılması
ÖZEN ALAHDAB Y., Kedrah A. E., GÜNDÜZ F., YÖNAL O., YILMAZ Y., ALAHDAB H., et al.
BUHASDER 6.Tepecik Enfeksiyon Günleri Sempozyumu, Muğla, Türkiye, 4 - 08 Kasım 2015
2015
201568. Nonalkolik Yağlı Karaciğerli Hastalarda İleri Evre Fibrozisin Saptanmasında Noninvazif Yeni Bir Yöntem Olan Fibrometer VCTE nin Tanısal Performansı
DİNÇSES E., YILMAZ Y.
32. Ulusal Gastroenteroloji Haftası, Türkiye, 25 - 29 Kasım 2015, cilt.26, ss.21
2015
201569. Aktif Kahverengi Yağ Dokusu Varlığı Yağlı Karaciğer Hastalığı Gelişimini Önlüyor Olabilir
Salih Ö., Tunç Ö., YILMAZ Y., TUROĞLU H. T., İMERYÜZ N.
32. Ulusal Gastroenteroloji Haftası, Türkiye, 25 - 29 Kasım 2015, cilt.26, ss.43-44
2015
201570. Non alcoholic steatohepatitis score is an independent predictor of right ventricular dysfunction in patients with non alcoholic fatty liver disease
SÜNBÜL M., KIVRAK T., DURMUŞ E., AKIN H., AYDIN Y., ERGELEN R., et al.
31. TURKISH CARDIOLOGY CONGRESS WITH INTERNATIONAL PARTICIPATION, 22 - 25 Ekim 2015
2015
201571. Can FibroMeter VCTE (TM) be useful for detecting hepatic fibrosis in patients with non-alcoholic fatty liver disease?
Dincses E., YILMAZ Y.
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Kostarika, 13 - 17 Kasım 2015, cilt.62, (Özet Bildiri)
2015
201572. Can FibroMeter VCTE be useful for detecting hepatic fibrosis in patients with non alcoholic fatty liver disease
DİNÇSES E., YILMAZ Y.
The AASLD Liver Meeting 2015, San-Francisco, Kostarika, 13 - 17 Kasım 2015, cilt.62, ss.1270
2015
201573. Yeni Antikoagülanlar İşlem öncesi ve sonrası yaklaşım
YILMAZ Y.
3.Gastrointestinal Endoskopi Günleri, İstanbul, Türkiye, 8 - 09 Mayıs 2015
2015
201574. Characterization of Lean Patients With Nonalcoholic Fatty Liver Disease Potential Role of High Hemoglobin Levels
AKYÜZ Ü., YEŞİL A., YILMAZ Y.
46th Annual Digestive Disease Week (DDW), Washington, Kiribati, 16 - 19 Mayıs 2015, cilt.148, ss.1058
2015
201575. Noninvasive tests in the diagnosis of Non Alcoholic Fatty Liver Disease
YILMAZ Y.
The 24th Conference of the Asian Pacific Association for the Study of Liver (APASL), İstanbul, Türkiye, 12 - 15 Mart 2015
2015
201576. Yağlı Karaciğer Non alkolik Steatohepatit ve Alkolik Steatohepatit
YILMAZ Y.
Uludağ İç Hastalıkları Kış Kongresi, Bursa, Türkiye, 08 Mart 2015
2015
201577. Hepatoselüler Karsinoma Karsinogenezde endokrin metabolik mekanizmalar
YILMAZ Y.
13. Hepatoloji Sempozyumu, Ankara, Türkiye, 17 Ocak 2015
2014
201478. Barsak karaciğeri nasıl etkiler
YILMAZ Y.
31. Ulusal Gastroenteroloji Haftası, Antalya, Türkiye, 24 - 28 Kasım 2014
2014
201479. Otoimmün hepatit ilaç hepatotoksisitesi yağlı karaciğer ve hepatitte yaklaşım ilaç seçimi ve izlem
YILMAZ Y.
A’dan Z’ye Psöriazis Toplantısı, İstanbul, Türkiye, 08 Kasım 2014
2014
201480. Klinik Araştırma Planlaması
YILMAZ Y.
11. Ulusal HEBİPA Kongresi, Kıbrıs (Kktc), 24 - 28 Eylül 2014
2014
201481. Alkol Dışı Yağlı Karaciğer Hastalığı
YILMAZ Y.
1. TÜRKİYE-AZERBAYCAN ORTAK HEPATOLOJİ KURSU, İstanbul, Türkiye, 18 - 19 Eylül 2014
2014
201482. Biodegradable Stentler
YILMAZ Y.
Türk Gastroenteroloji Derneği İstanbul Şubesi Mezuniyet Sonrası Eğitim Toplantısı, İstanbul, Türkiye, 25 Haziran 2014
2014
201483. Fibrokistik Karaciğer Hastalıkları
YILMAZ Y.
Türk Karaciğer Araştırmaları Derneği Mezuniyet Sonrası Eğitim Toplantısı, İstanbul, Türkiye, 13 Haziran 2014
2014
201484. KC biyopsi Fibroscan uygulamaları
AYGÜN C., YILMAZ Y.
5. Hepatoloji Okulu, Kocaeli, Türkiye, 30 Mayıs - 01 Haziran 2014
2014
201485. Karaciğer Transplantasyonlu Hastalarda Metabolik Komplikasyonlar ve Sorunların Yönetimi
YILMAZ Y.
Organ Nakilleri Bilinçlendirme ve Geliştirme DerneğiKaraciğer Nakli Mezuniyet Sonrası Eğitim Kursu 1, İstanbul, Türkiye, 24 Mayıs 2014
2014
201486. Alkol Dışı Yağlı Karaciğer Hastalıkları
YILMAZ Y.
İSTAHED Kongresi Viral Hepatitler ve Diğer Hepatobilier hastalıklarda Klinik Yaklaşım Kursu, Antalya, Türkiye, 10 Mayıs 2014
2014
201487. Nonalkolik yağlı karaciğer Nonalkolik steatohepatit
YILMAZ Y.
Türk Karaciğer Vakfı Mezuniyet Sonrası Eğitim Toplantıları, İstanbul, Türkiye, 29 Mart 2014
2014
201488. Erişkinde Yağlı Karaciğer Hastalığı ve Yönetimi Yenilik var mı
YILMAZ Y.
Karaciğer Hastalıkları ve Transplantasyonu Güncelleme Toplantısı, İstanbul, Türkiye, 01 Mart 2014
2014
201489. Are patients with biopsy proven non alcoholic fatty liver disease at increased risk of asthma Results from a Turkish cross sectional study
TAŞLI B., YILMAZ Y.
The Asian Pacific Society of Respirology 19th Congress, Balvi, Letonya, 13 - 16 Kasım 2014, cilt.19, ss.173-203
2013
201390. Fibroscan aracılı CAP kronik karaciğer hastalıklarında yağlanmanın şiddetini hastalık etyolojisinden ve fibrozisten bağımsız olarak doğru tahmin eder
YILMAZ Y., YEŞİL A., GERİN F., ERGELEN R., AKIN H., ÇELİKEL Ç., et al.
30. Ulusal Gastroenteroloji Haftası, Türkiye, 11 - 15 Ekim 2013
2013
201391. CAP yöntemli Fibroscan ile karaciğer yağlanmasının kantitatif değerlendirilmesi Karaciğer biyopsisi ile karşılaştırmalı prospektif çalışma
YILMAZ Y., YESIL A., GERİN F., ERGELEN R., AKIN H., ÇELİKEL Ç., et al.
30. Ulusal Gastroenteroloji Haftası, Türkiye, 11 - 15 Ekim 2013
2013
201392. Evaluation of gallbladder kinetics in patients with nonalcoholic fatty liver disease
Colak Y., Bozbey G., Senates E., Doganay L., Coskunpinar E., Ozturk O., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 Kasım 2013, cilt.58, (Özet Bildiri)
2013
201393. NAFLD da Metformin Hiç Vermeyelim mi
YILMAZ Y.
10.Ulusal Hepato Gastroenteroloji Kongresi, Magosa, Kıbrıs (Kktc), 25 - 29 Eylül 2013
2013
201394. Mikrobiyota ve Nonalkolik Yağlı Karaciğer Hastalığı
YILMAZ Y.
30. Ulusal Gastroenteroloji Haftası, Antalya, Türkiye, 11 - 15 Eylül 2013
2013
201395. HEPATIC EXPRESSION AND SERUM LEVELS OF SYNDECAN 1 (CD138) IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Yilmaz Y., Eren F., Colak Y., Senates E., Celikel Ç., Imeryuz N.
International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Hollanda, 24 - 28 Nisan 2013, cilt.58, (Özet Bildiri)
2013
201396. HYPOTHYROIDISM IS NOT ASSOCIATED WITH SPECIFIC HISTOLOGICAL FEATURES OR SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE
Yilmaz Y., Ayyildiz T., Colak Y., Senates E., Arabul M., Unsal B., et al.
International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Hollanda, 24 - 28 Nisan 2013, cilt.58, (Özet Bildiri)
2013
201397. GALLSTONE DISEASE IS NOT ASSOCIATED WITH LIVER FIBROSIS AND NONALCOHOLIC STEATOHEPATITIS IN NONALCOHOLIC FATTY LIVER DISEASE
Yilmaz Y., Ayyildiz T., Akin H., Colak Y., Ozturk O., Senates E., et al.
International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Hollanda, 24 - 28 Nisan 2013, cilt.58, (Özet Bildiri)
2013
201398. A BIOMARKER PANEL WITH HIGH SENSITIVITY AND SPECIFICITY FOR NONALCOHOLIC STEATOHEPATITIS IDENTIFIED BY SUPPORT VECTOR MACHINE
Yilmaz Y., Eren F.
International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Hollanda, 24 - 28 Nisan 2013, cilt.58, (Özet Bildiri)
2013
201399. Metabolik Sendrom ve NAYK PAtogenezde Yenilikler
YILMAZ Y.
11. Hepatoloji Sempozyumu, Ankara, Türkiye, 18 - 19 Ocak 2013
2012
2012100. NAFLD patogenezinde yeni ne var Steatoz koruyucu bir mekanizma mıdır
YILMAZ Y.
29. Ulusal Gastroenteroloji Haftası, Antalya, Türkiye, 20 - 25 Kasım 2012
2012
2012101. NASH Tedavisinde Yenilikler
YILMAZ Y.
9. Ulusal HepatoGastroenteroloji Kongresi, Magosa, Kıbrıs (Kktc), 26 - 30 Eylül 2012
2012
2012102. Non viral Hepatoselüler Kanser Etyolojisi NAFLD Alkol ve Diğer Faktörler
YILMAZ Y.
4. Hepatoloji Okulu, Muğla, Türkiye, 25 - 26 Mayıs 2012
2012
2012103. Patogenezde VAT mı önemli SAT mı Günlük yaşamda fruktoz sanıldığı kadar suçlu mu
YILMAZ Y.
NAFLD Sempozyumu, Ankara, Türkiye, 24 Mart 2012
2011
2011104. Association of MDRI Gene and Helicobacter pylori in the Development of Gastric Cancer and Gastritis
Eren F., Imeryuz N., Bas E., Ozkan N., Ozdemir F. T., Yilmaz Y., et al.
Conference on Digestive Disease Week 2011, Illinois, Amerika Birleşik Devletleri, 7 - 10 Mayıs 2011, cilt.140, (Özet Bildiri)
2011
2011105. CIRCULATING LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGF) AND ITS SOLUBLE RECEPTOR SVEGFR-1 IN PATIENTS WITH BIOPSY-PROVEN NONALCOHOLIC FATTY LIVER DISEASE
Yilmaz Y., Alahdab Y. O., Kurt R., Yonal O., Eren F., Kalayci C., et al.
46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Berlin, Almanya, 30 Mart - 03 Nisan 2011, cilt.54, (Özet Bildiri)
2011
2011106. SERUM LEVELS OF OSTEOPROTEGERIN IN THE SPECTRUM OF NONALCOHOLIC FATTY LIVER DISEASE
Yilmaz Y., Yonal O., Kurt R., Eren F., Imeryuz N., Kalayci C., et al.
46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Berlin, Almanya, 30 Mart - 03 Nisan 2011, cilt.54, (Özet Bildiri)
2009
2009107. PLASMA LEVELS OF SOLUBLE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS (SRAGE) IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Yilmaz Y., Ulukaya E., Gul O. O., Arabul M., Gul C. B., Atug O., et al.
44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Copenhagen, Danimarka, 22 - 26 Nisan 2009, cilt.50, (Özet Bildiri)
Kitaplar
2021
20211. Covid-19 ve Karaciğer Yağlanması İlişkisi Nasıl Gelişmektedir?
Demirtaş C. Ö., YILMAZ Y.
Türkiye Klinikleri Gastroenteroloji ve Covid-19, Ahmet Uygun, Editör, Türkiye Klinikleri, Ankara, ss.39-44, 2021
2020
20202. Non-alcoholic Fatty Liver Disease: A Global Public Health Issue
Kaya E., Yılmaz Y.
Obesity and Diabetes, Joel Faintuch,Salomão Faintuc, Editör, Springer-Verlag , Zürich, ss.1-987, 2020
2020
20203. Alkol Dışı Yağlı Karaciğer Hastalığı
KEFELİ A., YILMAZ Y.
Hepatobiliyer Sistem ve Pankreas Hastalıkları, Kefeli, Ayşe, Editör, Akademisyen Yayınevi, Ankara, ss.193-209, 2020
2020
20204. Non-alcoholic Fatty Liver Disease: A Global Public Health Issue
KAYA E., YILMAZ Y.
Obesity and Diabetes, Faintuch, Joel, Faintuch, Salomão, Editör, Springer, ss.321-333, 2020
2019
20195. Türkiye’de ve Dünyada Nonalkolik Yağlı Karaciğer Hastalığı Epidemiyolojisi
Kaya E., Yılmaz Y.
Türkiye Klinikleri Gastroenterohepatoloji-Özel Konular: Nonalkolik Yağlı Karaciğer Hastalığı, Abdullah Sonsuz, Editör, Türkiye Klinikleri (Ortadoğu Reklam Tanıtım Yayıncılık), Ankara, ss.1-7, 2019
2019
20196. Türkiye’de ve Dünyada Nonalkolik Yağlı Karaciğer Hastalığı Epidemiyolojisi
Kaya E., YILMAZ Y.
Türkiye Klinikleri Gastroenterohepatoloji-Özel KonularNonalkolik Yağlı Karaciğer Hastalığı, Abdullah Sonsuz, Editör, Türkiye Klinikleri (Ortadoğu Reklam Tanıtım Yayıncılık), Ankara, ss.1-7, 2019
2016
20167. Is NAFLD different in absence of metabolic syndrome?
Yılmaz Y.
Clinical Dilemmas in Non Alcoholic Fatty Liver Disease, Roger Williams,Simon D. Taylor-Robinson, Editör, Wiley-VCH Verlag Weinheim GmbH , London, ss.50-57, 2016
2015
20158. Obesity-Associated Nonalcoholic Fatty Liver Disease
YILMAZ Y., YOUNOSSI Z. M.
OBESITY A Multidisciplinary Approach, Joel J. Heidelbaugh, Editör, ELSEVIER, Philadelphia, ss.93-107, 2015
Bilimsel Dergilerdeki Faaliyetler
2020 - Devam Ediyor
2020 - Devam EdiyorHepatology Forum
Yardımcı Editör/Bölüm Editörü
2020 - Devam Ediyor
2020 - Devam EdiyorAlimentary Pharmacology & Therapeutics
Editörler Kurulu Üyesi
Bilimsel Kuruluşlardaki Üyelikler / Görevler
2011 - Devam Ediyor
2011 - Devam EdiyorEuropean Association for the Study of the Liver
Üye
Bilimsel Yayınlarda Hakemlikler
Eylül 2020
Eylül 2020International Journal of Medical Arts
ESCI Kapsamındaki Dergi
Eylül 2020
Eylül 2020TURKISH JOURNAL OF GASTROENTEROLOGY
SCI-E Kapsamındaki Dergi
Eylül 2020
Eylül 2020TURKISH JOURNAL OF GASTROENTEROLOGY
SCI-E Kapsamındaki Dergi
Eylül 2020
Eylül 2020GASTROENTEROLOGY RESEARCH AND PRACTICE
SCI Kapsamındaki Dergi
Ağustos 2020
Ağustos 2020BIOMED RESEARCH INTERNATIONAL
SCI-E Kapsamındaki Dergi
Ağustos 2020
Ağustos 2020İSTANBUL TIP FAKÜLTESİ DERGİSİ
Hakemli Bilimsel Dergi
Ağustos 2020
Ağustos 2020ARCHIVES OF MEDICAL RESEARCH
SCI Kapsamındaki Dergi
Ağustos 2020
Ağustos 2020JOURNAL OF DIABETES AND ITS COMPLICATIONS
SCI-E Kapsamındaki Dergi
Temmuz 2020
Temmuz 2020JGH Open
ESCI Kapsamındaki Dergi
Temmuz 2020
Temmuz 2020JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
Hakemli Bilimsel Dergi
Temmuz 2020
Temmuz 2020ALIMENTARY PHARMACOLOGY & THERAPEUTICS
SCI Kapsamındaki Dergi
Temmuz 2020
Temmuz 2020DIABETES RESEARCH AND CLINICAL PRACTICE
SCI-E Kapsamındaki Dergi
Temmuz 2020
Temmuz 2020Clinical and Molecular Hepatology
ESCI Kapsamındaki Dergi
Temmuz 2020
Temmuz 2020HEPATOBILIARY SURGERY AND NUTRITION
SCI Kapsamındaki Dergi
Haziran 2020
Haziran 2020BMC GASTROENTEROLOGY
SCI Kapsamındaki Dergi
Haziran 2020
Haziran 2020CHINESE MEDICAL JOURNAL
SCI-E Kapsamındaki Dergi
Mayıs 2020
Mayıs 2020CANADIAN JOURNAL OF GASTROENTEROLOGY
SCI-E Kapsamındaki Dergi
Mayıs 2020
Mayıs 2020ALIMENTARY PHARMACOLOGY & THERAPEUTICS
SCI Kapsamındaki Dergi
Mayıs 2020
Mayıs 2020Exploration of Medicine
Diğer İndekslerce Taranan Dergi
Mart 2020
Mart 2020LIVER INTERNATIONAL
SCI Kapsamındaki Dergi
Mart 2020
Mart 2020ALIMENTARY PHARMACOLOGY & THERAPEUTICS
SCI Kapsamındaki Dergi
Temmuz 2019
Temmuz 2019TURKISH JOURNAL OF GASTROENTEROLOGY
SCI-E Kapsamındaki Dergi
Haziran 2019
Haziran 2019TURKISH JOURNAL OF GASTROENTEROLOGY
SCI-E Kapsamındaki Dergi
Mayıs 2019
Mayıs 2019ALIMENTARY PHARMACOLOGY & THERAPEUTICS
SCI Kapsamındaki Dergi
Mart 2019
Mart 2019TURKISH JOURNAL OF GASTROENTEROLOGY
SCI-E Kapsamındaki Dergi
Şubat 2019
Şubat 2019TURKISH JOURNAL OF GASTROENTEROLOGY
SCI-E Kapsamındaki Dergi
Kasım 2016
Kasım 2016JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
SCI Kapsamındaki Dergi
Kasım 2016
Kasım 2016LIVER INTERNATIONAL
SCI Kapsamındaki Dergi
Ekim 2016
Ekim 2016ALIMENTARY PHARMACOLOGY & THERAPEUTICS
SCI Kapsamındaki Dergi
Eylül 2015
Eylül 2015LIVER INTERNATIONAL
SCI Kapsamındaki Dergi
Temmuz 2015
Temmuz 2015TURKISH JOURNAL OF GASTROENTEROLOGY
SCI-E Kapsamındaki Dergi
Haziran 2015
Haziran 2015JOURNAL OF HEPATOLOGY
SCI Kapsamındaki Dergi
Haziran 2015
Haziran 2015JOURNAL OF HEPATOLOGY
SCI Kapsamındaki Dergi
Mayıs 2015
Mayıs 2015TURKISH JOURNAL OF GASTROENTEROLOGY
SCI-E Kapsamındaki Dergi
Nisan 2015
Nisan 2015TURKISH JOURNAL OF GASTROENTEROLOGY
SCI-E Kapsamındaki Dergi
Ağustos 2014
Ağustos 2014LIVER INTERNATIONAL
SCI Kapsamındaki Dergi
Haziran 2014
Haziran 2014LIVER INTERNATIONAL
SCI Kapsamındaki Dergi
Nisan 2013
Nisan 2013EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
SCI Kapsamındaki Dergi
Ödüller
Temmuz 2020
Temmuz 2020'Dünyanın En Etkili Bilim İnsanları Listesi'nde Türkiye'den Gastroenteroloji alanındaki tek kişi
Plos Biology
Kongre ve Sempozyum Katılımı Faaliyetleri
01 Kasım 2019 - 01 Kasım 2019
01 Kasım 2019 - 01 Kasım 2019AASLD Annual Meeting
Çalışma Grubu
Massachusetts-Amerika Birleşik Devletleri
21 Eylül 2019 - 24 Eylül 2019
21 Eylül 2019 - 24 Eylül 2019World Congress of Gastroenterology
Davetli Konuşmacı
İstanbul-Türkiye
01 Eylül 2019 - 01 Eylül 2019
01 Eylül 2019 - 01 Eylül 2019The NAFLD Summit 2019
Çalışma Grubu
Sevilla-İspanya
01 Haziran 2019 - 01 Haziran 2019
01 Haziran 2019 - 01 Haziran 2019International Conference on Fatty Liver,
Çalışma Grubu
Berlin-Almanya
01 Mayıs 2019 - 01 Mayıs 2019
01 Mayıs 2019 - 01 Mayıs 2019Digestive Disease Week
Çalışma Grubu
California-Amerika Birleşik Devletleri
01 Nisan 2019 - 01 Nisan 2019
01 Nisan 2019 - 01 Nisan 2019The EASL International Liver Congress
Çalışma Grubu
Vienna-Avusturya
28 Mart 2019 - 31 Mart 2019
28 Mart 2019 - 31 Mart 201917th Euroasian Congress of Hepato-Gastroenterology and Surgery
Davetli Konuşmacı
Split-Hırvatistan
15 Mart 2019 - 16 Mart 2019
15 Mart 2019 - 16 Mart 2019AASLD TASL Regional Connect Meeting
Davetli Konuşmacı
İstanbul-Türkiye
01 Şubat 2019 - 01 Şubat 2019
01 Şubat 2019 - 01 Şubat 2019Asian Pacific Association for the Study of the Liver Annual Meeting
Çalışma Grubu
Manila-Filipinler
09 Kasım 2018 - 10 Kasım 2018
09 Kasım 2018 - 10 Kasım 2018Global NASH Council Meeting
Davetli Konuşmacı
California-Amerika Birleşik Devletleri
22 Eylül 2016 - 24 Eylül 2016
22 Eylül 2016 - 24 Eylül 2016APASL Single Topic Conference
Davetli Konuşmacı
İstanbul-Türkiye
24 Kasım 2015 - 25 Kasım 2015
24 Kasım 2015 - 25 Kasım 2015FRONTIERS IN HEPATOLOGY Non-alcoholic Fatty Liver Disease & the Metabolic Syndrome – Key questions on disease consequences and treatment
Davetli Konuşmacı
London-Birleşik Krallık
Atıflar
Toplam Atıf Sayısı (WOS): 5458
h-indeksi (WOS): 34
Jüri Üyelikleri
Ağustos-2020
Ağustos 2020Doçentlik Sınavı
- Üniversitelerarası Kurul
Bilimsel Araştırma / Çalışma Grubu Üyelikleri
2020 - Devam Ediyor
2020 - Devam EdiyorYağlı Karaciğer Çalışma Grubu
http://www.tasl.org.tr/
Türk Karaciğer Araştırmaları Derneği, Turkey
2018 - Devam Ediyor
2018 - Devam EdiyorThe Global Nash Council
https://www.corld.org/global-nash-council/
Center for Outcomes Research in Liver Diseases, Turkey
2018 - Devam Ediyor
2018 - Devam Ediyor